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1. Introduction 
1.1 Epidemiology 
Lung cancer is the leading cause of cancer-related deaths worldwide, with a poor 
five-year survival rate of approximately 15%. It accounts for more deaths than the 
next four most lethal cancer types combined (Jett and Midthun 2004; Eramo et al. 
2008; Mallick et al. 2010) (Figure 1). Lung cancer is usually detected as an accidental 
finding at an advanced stage or when symptoms are clinically present (Brambilla et 
al. 2003). In order to decrease these high mortality rates, screening techniques and 
reliable biomarkers are needed. 
 
 
Figure 1: Incidence and mortality rates of different cancers, evaluated by the WHO World 
Cancer Report 2008 for the European region (Boyle 2008). Lung cancer accounts for more 
deaths than the next four most lethal cancer types combined. 
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Twenty-five percent of all lung tumours are neuroendocrine tumours (NETs) 
(Rekhtman 2010). This subset of tumours encompasses small-cell lung carcinoma 
(SCLC), large-cell neuroendocrine carcinoma (LCNEC) and both typical (TC) and 
atypical carcinoid (AC) (Takei et al. 2002). Although the incidence of pulmonary 
carcinoids has increased during the past 30 years, their combined incidence (both 
TCs and ACs) in 2003 was just 1.57 per 100,000 inhabitants in the USA (Swarts et 
al. 2012). Patients suffering from TC have excellent survival rates of 87-100%, but 
some present lymph node metastasis (4-15%) (Travis et al. 1998; Beasley et al. 
2000; Fink et al. 2001; Thomas et al. 2001; Cardillo et al. 2004; Pelosi et al. 2005; 
Asamura et al. 2006; Garcia-Yuste et al. 2007; Rea et al. 2007; Travis 2009). ACs 
are more aggressive and show higher frequency of nodal metastasis (35-64%). The 
survival rate is 61-88% (Beasley et al. 2000; Fink et al. 2001; Scott 2003; Cardillo et 
al. 2004; Pelosi et al. 2005; Asamura et al. 2006; Garcia-Yuste et al. 2007; Rea et al. 
2007). Patients suffering from TC and AC have a mean age at diagnosis of 45-55 
years (Travis 2009). 
 
LCNEC was only recognized for the first time about a decade ago. LCNEC belongs 
to the non-SCLC tumours according to the 1999 WHO classification, but it shows a 
similar clinical progression to SCLC, with a five-year survival between 15% and 57%, 
depending on the reporting source (Asamura et al. 2006; Rekhtman 2010). 
Approximately 15% of all lung cancers are SCLCs, showing definite neuroendocrine 
differentiation (Rekhtman 2010), and metastasize early (Takei et al. 2002; Asamura 
et al. 2006; Travis 2009). Ninety-five percent of all small-cell carcinomas (SCCs) are 
found in the lung, whereas non-pulmonary SCCs are very rare (Rekhtman 2010). The 
five-year survival for SCLC is <5% (Rekhtman 2010). Even when diagnosed at an 
early stage, SCLCs and LCNECs show the poorest clinical outcome compared to 
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other lung tumours due to their aggressive biological behaviour. However, the 
molecular characteristics of these tumours remain incompletely understood (Takei et 
al. 2002). They grow rapidly and occur almost exclusively in patients with a history of 
heavy smoking, whereas lung carcinoids occur frequently in never smokers and 
younger patients (Travis et al. 1998; Travis et al. 2004; Travis 2009; Swarts et al. 
2012). Although both LCNEC and SCLC are still more common in males, the 
proportion of women suffering from these has significantly increased due to the 
altered smoking habits of women (Govindan et al. 2006; Swarts et al. 2012). 
Table 1 summarizes the outcomes for patients suffering from pulmonary tumours with 
neuroendocrine features from a recent study. 
 
Table 1. Comparison of clinical parameters from patients suffering from NET (Asamura et al. 
2006).  
 Histologic Type    
 TC  AC  LCNEC  SCLC  Total 
 (n=55)  (n=9)  (n=141)  (n=113)  (N=318) 
 No. of   No.  of   No. of   No.  of   No. of  
Outcome Patients %  Patients %  Patients %  Patients %  Patients % 
Tumour recurrence 2 3.6  3 33.3  68 48.2  54 47.8  124 39 
Locoregional 1   1   17   10   30  
Distant 1   2   34   18   55  
Both 0   0   16   16   36  
Unknown 0   0   1   1   4  
All deaths 3 5.5  2 22.2  84 59.6  69 61.1  158 49.7 
Cancer death 0 0.0  0 0.0  62 73.8  43 63.2  106 67.5 
Abbreviations: TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell lung carcinoma; 
NE, neuroendocrine 
 
1.2 Tumorigenesis 
Tumorigenesis is a complex event on the cellular level comprising the following six 
deregulation criteria: (I) autonomous growth, (II) insensitivity to external growth-
regulating signals and (III) resistance to apoptotic signals, (IV) increased proliferation, 
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(V) as well as permanent angiogenesis and (VI) metastatic behaviour (Zhu et al. 
2006). 
During carcinogenesis, cells accumulate multiple molecular-genetic and epigenetic 
abnormalities that lead to immortalisation, uncontrolled proliferation and spread of 
these cells (Brambilla et al. 2003). 
 
Cell of Origin 
Both pulmonary carcinoids and SCLCs were previously reported to arise from 
serotonin producing Kulchitsky-type cells, currently known as pulmonary 
neuroendocrine cells (PNECs), which are the first cells to differentiate in the 
epithelium during lung development (Bensch et al. 1968; Warburton et al. 2000; 
Swarts et al. 2012). Sometimes they aggregate to form small nodules named 
neuroepithelial bodies (NEBs). PNECs only comprise about 0.4% of bronchial 
epithelial cells, playing an important role as local modulators of lung growth and 
pulmonary differentiation during prenatal development and as airway chemoreceptors 
during adult life (Boers et al. 1996; Linnoila 2006; Swarts et al. 2012). In the prenatal 
phase, PNECs express serotonin, neuron-specific enolase (NSE) and gastrin-
releasing peptide, whereas in adults, NEBs have been described as being involved in 
hypoxia response by secretion of serotonin and thereby regulating local 
vasoconstriction (Cutz and Jackson 1999; Linnoila 2006; Swarts et al. 2012).   
Because gene expression profiling has shown that SCLCs cluster together with 
LCNECs, and combined SCLC-LCNEC tumours are not uncommon, it is suggested 
that LCNEC and SCLC originate from the same or similar precursor cells (Jones et 
al. 2004; Swarts et al. 2012). However, it remains unclear how carcinoids can be 
integrated into this scheme (Figure 2).  
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Precursor Lesions 
Precursor lesions of pulmonary carcinoid tumours comprise diffuse idiopathic 
pulmonary neuroendocrine cell hyperplasia (DIPNECH), a linear proliferation of 
PNECs or NEBs, as well as tumourlets (Swarts et al. 2012). Tumourlets are 2-5mm 
extraluminal lesions which share histopathological features with carcinoids and 
originate when proliferating PNECs penetrate through the basal membrane and form 
small aggregates; by definition, a tumourlet >5mm in size is termed a “carcinoid 
tumour” (Finkelstein et al. 1999). Although tumourlets are thought of as benign 
tumours, some have been reported to behave like carcinoids, cause Cushing’s 
syndrome and to metastasize to lymph nodes or even distant organs (D'Agati and 
Perzin 1985; Arioglu et al. 1998; Liu et al. 2003; Swarts et al. 2012). In contrast to 
tumourlets related to DIPNECH, tumourlets resulting from reactive PNEC hyperplasia 
do not progress to carcinoid tumours (Swarts et al. 2012). 
In contrast, no precursor lesions for high-grade lung NETs have been identified thus 
far, although genomic changes typical of these tumours have been observed in 
phenotypically normal cells (Lantuejoul et al. 2009). 
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Figure 2 Current model for the cells of origin of the main types of lung cancer. An Ash1 
expressing precursor cell is considered a stem cell giving rise to pulmonary neuroendocrine 
cells (PNECs), but also bronchoalveolar stem cells (BASC) and basal cell progenitors. 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and tumourlets 
comprise precursor lesions for pulmonary carcinoids, while for LCNEC and SCLC no 
precursor lesions have been identified. For adenocarcinoma, the precursor lesions seem to 
be atypical adenomatous hyperplasia (AAH) and bronchoalveolar carcinoma in situ (BAC). 
for squamous cell carcinoma, the bronchial squamous dysplasia is a suspected precursor 
lesion. (Swarts et al. 2012) C: central; P: lung periphery  
 
Models of Tumorigenesis 
A hypothetical model for carcinogenesis of pulmonary neuroendocrine tumours 
suggests an Ash1-positive pulmonary precursor cell capable of differentiation into 
PNECs, BASCs and basal cell progenitors (Swarts et al. 2012). 
 
In carcinoids, the transition towards tumourlets is initiated via a linear expansion of 
PNECs or NEBs into DIPNECH and a subsequent resistance to apoptotic 
mechanisms due to increased Bcl-2 expression (Gosney et al. 2011). Evasion of cell 
 
 
12 
cycle control must also be amongst the earliest stages (Swarts et al. 2012). 
Epigenetic silencing of tumour suppressor genes is also likely to occur in early 
tumorigenesis, e.g., involving RASSF1A methylation (Toyooka et al. 2001; Swarts et 
al. 2012). Subsequent steps in carcinoid progression may include abrogation of the 
Menin pathway, deletions of the telomeric part of chromosome 11q and CD44 
downregulation (Granberg et al. 1999; Swarts et al. 2012). Progression to a 
metastatic stage may result from epithelial-mesenchymal transition (EMT), probably 
induced by abolition of CDH1 (E-cadherin) or CTNNB1 (β-catenin) function along 
with an increase of the PSA variant of neural cell adhesion molecule 1 (NCAM; 
CD56) (Figure 3). 
 
The majority of steps in SCLC carcinogenesis can be related to direct exposure to 
tobacco carcinogens. Early events in carcinogenesis of this tumour include 
epigenetic changes and allelic imbalances such as 3p regions, comprising FHIT and 
RASSF1A, which can both be inactivated by promoter hypermethylation (Gorgoulis et 
al. 2005). Furthermore, aberrations of the intrinsic apoptosis pathway by inversion of 
the Bcl-2/Bax ratio are an early event, possibly preceding p53 alterations (Brambilla 
et al. 1998; Swarts et al. 2012). It is still unclear whether 3p deletions precede or 
follow 17p losses and associated p53 mutations (Swarts et al. 2012). A strict 
sequence of events in SCLC and LCNEC tumorigenesis like those reported for other 
human malignancies is therefore unlikely (Swarts et al. 2012). It is possible that p53 
mutations pave the way for subsequent chromosomal instability and further 
chromosomal losses like 9p, 17p and/or 5q, and might cause an inactivation of pRb 
and an increase in the PSA variant of NCAM downstream of this process, the next 
important events in tumorigenesis of high-grade pulmonary NET (Swarts et al. 2012). 
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Continued cigarette smoking may induce EMT, crucial for metastatic SCLC in 
association with MYC overexpression (Wong et al. 1986; Takahashi et al. 1989).  
Because there is a major lack of information regarding LCNEC, this tumour entity 
could not be included in this model (Swarts et al. 2012) (Figure 3). 
 
 
Figure 3 Tumorigenesis model for pulmonary neuroendocrine tumours excluding LCNEC.  
Precursor lesions are indicated in the grey area. The occurrences of specific aberrations in 
the primary tumour are shown. The dotted lines indicate hypothetical relationships (Swarts et 
al. 2012). C: central; P: lung periphery  
 
1.3 Diagnosis 
The morphologic features of carcinoid tumours have been accurately described: 
neuroendocrine cytology including coarsely granular “salt and pepper” chromatin, 
lack of prominent nucleoli and overall uniformity (Figure 4) (Travis et al. 2004; 
Rekhtman 2010). In addition, architectural patterns, like organoid nests, trabeculae or 
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rosettes, are morphological features of carcinoids (Figure 4 to Figure 5) (Travis et al. 
2004; Rekhtman 2010). Further diagnostic criteria for typical carcinoids include a 
mitosis rate of not more than 1 per 10 high power fields (HPF, approx. 2mm2) and an 
absence of necrotic areas. Atypical carcinoids are defined as showing a mitosis rate 
of 2-10 per 10 HPF and may exhibit areas of comedo-like necrosis (Travis et al. 
2004; Rekhtman 2010).  
 
Travis et al. (Travis et al. 1991) introduced LCNECs in the 2004 WHO classification 
and described their components. The high mitotic rate (>10 per 10 HPFs) and 
necrotic areas are criteria for these high grade carcinomas. The morphology is 
characterised by neuroendocrine architecture like organoid nesting, trabecular growth 
and palisade or rosette patterns (Figure 6). Cytology demonstrates prominent 
nucleoli, vesicular clumpy chromatin and large cell size (Travis et al. 2004; Rekhtman 
2010).  
 
Morphologically, SCLC are characterized by finely granular nuclear chromatin, 
nuclear moulding, lack of prominent nucleoli and crush artefacts with nuclear 
streaming and incrustation of vessels (Figure 7) (Travis et al. 2004; Rekhtman 2010). 
The size of the cells is normally less than three resting lymphocytes in extension 
(Travis et al. 2004; Rekhtman 2010). Other diagnostic features of SCLC include the 
high mitosis rate (>10 per 10 HPF) and undefined cell borders with apoptotic or 
necrotic areas (Hirsch et al. 1982; Travis et al. 2004).  
 
Diagnostic discrimination of LCNEC versus atypical carcinoids and SCLCs on solely 
morphological grounds is difficult due to overlapping morphological features. 
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Therefore, diagnosis by immunohistochemical (IHC) staining is a routine tool for 
differential diagnosis of neuroendocrine tumours. 
 
 
Figure 4 Typical carcinoid stained with haematoxylin and eosin (HE) showing 
neuroendocrine features such as rosettes (marked) and granular chromatin (400x 
magnification). Note the dense vascularisation of the tumour tissue. 
 
 
Figure 5 Atypical carcinoid with two rosette structures (circles) and “salt and pepper 
chromatin” (arrow) stained with HE (400x magnification).  
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Figure 6 Large-cell lung cancer forming a so-called palisade structure (400x magnification).   
 
 
Figure 7 Small-cell lung cancer with HE staining (400x magnification). The neuroendocrine 
properties like granular chromatin and lack of prominent nucleoli serve as diagnostic criteria 
for diagnosis of SCLC. 
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The most important markers for the diagnosis of pulmonary neuroendocrine tumours  
by IHC are neural cell adhesion molecule 1 (also known as CD56 or NCAM1), 
chromogranin A (CHGA), synaptophysin (SYP), thyroid transcription factor 1 (also 
known as TTF-1 or NKX21) and MKI67 (marker of proliferation Ki-67, also known as 
MIB1) (Takei et al. 2002; Asamura et al. 2006; Rekhtman 2010). As with all 
subjective imaging methods, these techniques are prone to significant intra- and 
interobserver variability, reducing the reproducibility and reliability of this 
methodology (Jagoe et al. 1991; Jarlov 2000; Asamura et al. 2006; Rekhtman 2010). 
Furthermore, differentiating LCNECs and SCLCs via IHC is hindered by their related 
biological characteristics, leading to false identification (Takei et al. 2002; Asamura et 
al. 2006; Rekhtman 2010). A reproducibility study by Travis et al. achieved 
unanimous agreement among five pathologists diagnosing LCNEC only 40% of the 
time (Travis et al. 1998). Furthermore, in an intraobserver variability study, only 12% 
of diagnoses were unanimous for a group of nine pathologists (den Bakker et al. 
2010). 
 
Zhu et al. (Zhu et al. 2006) performed a meta-analysis of literature focusing on 
tumour markers and their prognostic values based on IHC analysis. Table 2 shows 
the results of their broad investigation, revealing that a large number of potential 
markers exist, but that results obtained can differ significantly (Zhu et al. 2006). 
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Table 2 Summary of meta-analyses of the results of studies on candidate 
immunohistochemistry markers for survival of patients with non-small cell lung cancer (Zhu et 
al. 2006). 
Marker First author Published studies 
Number of 
eligible studies 
Number of 
patients 
Overall 
HR* 95% CI Significance/ comment 
EGFR Meert(Meert 
et al. 2002) 
Until July 2001 8 1987 1.13 1.00 to 1.28 Weak significance 
P21RAS Mascaux(Ma
scaux et al. 
2005) 
Until July 2003 7 989 1.08 0.86 to 1.34 Not significant 
HER-2 Nakamura 
(Nakamura 
et al. 2005) 
Until August 2004 18 2579 1.32 1.14 to 1.65 17/25 negative studies 
excluded for lack of detailed 
survival data 
P53 Steels 
(Steels et al. 
2001) 
Until July 1999 8 (Pab 1801)  
16 (DO-7) 
1035 1.57 1.28 to 1.91 True significance requires 
prospective and multivariante 
confirmation by a standardised 
technique, scoring criteria and 
cut-offs 
Ki-67 Martin 
(Martin et al. 
2004) 
Until December 
2002 
16 1863 1.55 1.34 to 1.78 
Bcl-2 Martin 
(Martin et al. 
2003) 
1993 to December 
1999 
18 2909 0.72 0.64 to 0.82 
CI, confidence interval; EGFR, epidermal growth factor receptor; HER; human epidermal growth factor receptor; HR, hazard ratio of death for high 
expression of the marker. 
*HR> 1 implies worse survival for the group with increased expression of the marker, whereas HR< 1 (Bcl-2) indicates better survival for the group 
with high expression. For p53, the prognostic significance of studies that used Pab1801 and DO7 antibodies were separately analysed. 
 
Tumour staging is performed based on several factors, trying to link them to the 
patients’ clinics and outcome. Tumour size, lymph node metastasis and distant 
metastasis as a part of TNM-staging cannot be taken as ultima ratio for prognosis. In 
general, late detection of a tumour with widespread metastases is associated with 
significantly decreased patient survival. As noted above, morphologic differentiation 
between LCNEC and SCLC can fail because of related histology, making molecular 
markers a favourable tool for more accurate tumour assessment (Asamura et al. 
2006).  
 
 
 
19 
1.4 Treatment of Pulmonary Neuroendocrine Tumours 
Due to the different treatment options for each malignant neuroendocrine lung 
tumour, accurate pathohistological diagnosis is crucial. Carcinoid tumours are 
predominantly surgically treated, based on the general principle of complete 
resection when locally limited. Metastatic tumours are commonly not sensitive to 
chemotherapeutic regimes or radiation therapy (Rekhtman 2010; Gridelli et al. 2012). 
Recurrence after surgical resection occurs in 3-5% of all TC (Gridelli et al. 2013). In 
AC, 25% of deaths are due to recurrences (Ducrocq et al. 1998; Gridelli et al. 2013). 
A mediastinal lymph node dissection is recommended for AC without the detection of 
lymph node invasion (Gridelli et al. 2013). TCs are polyp-like endobronchial 
structures without extension through the cartilaginous wall in 5-10% of patients; 
however, endobronchial removal should be reserved for very specific patients 
(Luckraz et al. 2006; Brokx et al. 2007). In the presence of central carcinoids with 
clinical invasion of lymph nodes, surgical resection and mediastinal lymph node 
dissection is recommended (Gridelli et al. 2013). Adjuvant treatment, chemotherapy 
or radiotherapy should be considered in completely resected ACs with mediastinal 
lymph node involvement (Thomas et al. 2001; Mackley and Videtic 2006; Gridelli et 
al. 2013). Combined chemotherapies are usually platinum- or streptozoticin-based 
approaches (Gridelli et al. 2013).  
 
For SCLCs, chemotherapy with cisplatin plus etoposide is an established treatment 
since the tumours are notably sensitive to chemotherapeutical and radiation therapy 
(Rekhtman 2010). A prophylactic cranial irradiation should be performed in SCLCs 
with a chemosensitive shape. Since 50-80% of patients develop brain metastases, a 
proper pathological diagnosis is vital (Rekhtman 2010). Considering the relative rarity 
of LCNEC (~3% of neuroendocrine lung tumours), an optimal treatment for this entity 
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is still under investigation (Rekhtman 2010). Under the WHO classification guidelines, 
LCNEC belongs to non-SCLCs, and based on this classification therapeutic 
strategies for LCNEC leave it up to clinicians whether to treat it similarly to SCLCs or 
non-SCLCs (Asamura et al. 2006). In fact, patients in stage IV receiving SCLC-based 
regimens had a significantly better overall survival rate compared with those 
receiving standard regimes for NSCLC (Rossi et al. 2005; Gridelli et al. 2013). The 
chemotherapy regimens usually administered in SCLC therapy, including platinum 
plus etoposide, should be the preferred option (Gridelli et al. 2013). Unfortunately, 
there is even less information available concerning the treatment of unresectable and 
advanced LCNEC (Gridelli et al. 2013). 
Most LCNECs are poor candidates for surgical resection due to local or systemic 
spread (Gridelli et al. 2013). In early stages, lobectomy or pneumonectomy are 
preferred (Zacharias et al. 2003; Gridelli et al. 2013).  
The American Society for Clinical Oncology (ASCO) and the European Society for 
Medical Oncology (ESMO) summarize these recommendations in their clinical 
practice guidelines (Rinaldi et al. 2006; Gridelli et al. 2013; Vansteenkiste et al. 
2013). 
 
Figure 8 provides a suggested algorithm for treatment decisions in non-small cell 
neuroendocrine lung tumours. 
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Figure 8 Suggested algorithm for the treatment of non-small cell pulmonary neuroendocrine 
tumours (Gridelli et al. 2013). 
 
Targeted Therapies 
Octreotide was developed as a pharmacologically stable, long-acting repeatable 
(LAR) analogue of the hormone somatostatin and has proven to be an effective 
agent for symptoms of carcinoid syndrome (Gridelli et al. 2013). Several results 
supported the recommendation of somatostatin analogues such as octreotide and 
lanreotide in treating the carcinoid syndrome, but their use for any other purpose, 
including the management of asymptomatic metastatic carcinoids, is still subject to 
fierce debate (Filosso et al. 2002; Waldherr et al. 2002; Srirajaskanthan et al. 2009; 
Bushnell et al. 2010; Oberg et al. 2010; Gridelli et al. 2013). 
The mammalian target of rapamycin (mTOR) pathway may be involved in the 
pathogenesis of neuroendocrine tumours and can be inhibited by everolimus (Gridelli 
et al. 2013). The upregulation of upstream insulin-like growth factor-1 (IGF1) pathway 
should be a potential resistance mechanism for everolimus (O'Reilly et al. 2006). In 
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contrast, octreotide has been shown to reduce serum IGF-1 levels in patients with 
solid tumours (Pollak et al. 1989).  
Overexpression of vascular endothelial growth factor (VEGF) and VEGF receptor 
(VEGFR) subtypes has been observed in carcinoid tumours, suggesting that 
autocrine activation of the VEGF pathway may promote tumour growth (La Rosa et 
al. 2003; Gridelli et al. 2013). In addition, neuroendocrine tumours also express 
platelet derived growth factor (PDGF) and PDGF receptor (PDGFR) (Chaudhry et al. 
1992), targets drugable with sunitinib, an orally administered small molecule with 
activity against VEGFR-1, -2, -3, PDGFR-α and –β (Mendel et al. 2003; Gridelli et al. 
2013). Results from the use of bevacizumab are also promising, but need to be 
confirmed in larger studies (Gridelli et al. 2013). Additionally, interferon-α (IFNA1) has 
been described as having antiangiogenic properties and has also been studied in 
carcinoids. In fact, it was approved by the European Medicines Agency (EMA) for the 
treatment of metastatic carcinoid tumours with syndrome (Gridelli et al. 2013). 
The role of the ErbB family signalling was investigated for this class of tumours 
(Rickman et al. 2009). The analysis showed that 45.8% of TCs and 28.6% of ACs 
expressed epidermal growth factor receptor (EGFR), all tumours lacked expression 
of ErbB2 and all had moderate or intense staining for ErbB3 and ErbB4. No EGFR 
mutations were found in a recent study and all investigated tumours were KRAS 
wildtype (Rickman et al. 2009). Moreover, in a lung carcinoid cell line expressing 
EGFR, erlotinib reduced proliferation. These findings suggest a potential clinical use 
of EGFR inhibitors in the treatment of patients with pulmonary carcinoids (Rickman et 
al. 2009; Gridelli et al. 2013). 
Targeted therapy of tyrosine kinase receptors also seems promising in SCLC. In 
particular, expression c-Kit receptor (KIT) has been widely studied within SCLC, 
showing that 56-70% of these tumours are positive for c-Kit expression (Swarts et al. 
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2012). PDGFR-β is also frequently expressed in SCLC (Shinohara et al. 2007; 
Swarts et al. 2012). As a result, an inhibitory effect of mesylate, a small molecule 
inhibitor which targets KIT as well as PDGFR and Bcr-Abl, could be shown in SCLC 
cell lines (Krystal et al. 2000). Hedgehog signalling reveals potential targets for 
therapy, because this pathway is implicated in the development and maintenance of 
SCLC. In particular, sonic hedgehog is expressed in a subset of SCLC (Watkins et al. 
2003; Park et al. 2011; Swarts et al. 2012). 
 
1.5 Molecular Differences and Similarities 
Genomic DNA Alterations 
Several genome-wide (array) comparative genomic hybridization (CGH) studies as 
well as other technical approaches were performed to identify chromosomal 
alterations in pulmonary carcinoids (Walch et al. 1998; Zhao et al. 2000; Leotlela et 
al. 2003; Petzmann et al. 2004), high grade lung NETs (Petersen et al. 1997; 
Michelland et al. 1999; Ullmann et al. 2001; Peng et al. 2005) or both (Peng et al. 
2005; Swarts et al. 2012) (Table 3). In general, chromosomal alterations of more than 
10 Mb in size are much more frequent in SCLCs and LCNECs than ACs and TCs 
(SCLC: 18.8/tumour, LCNEC: 13.7/tumour, AC: 6.1/tumour, TC: 2.8/tumour) (Swarts 
et al. 2012). Although most alterations occur frequently in both high-grade tumour 
types, it must be noted that loss of chromosome 17p (harbouring the TP53 gene 
locus) and gain of 3q occur twice as frequently in SCLCs compared to LCNECs 
(Swarts et al. 2012). 
The most important chromosomal alteration in neuroendocrine lung carcinomas, 
which is infrequently present in lung carcinoids, is deletion of chromosome 3p 
(Swarts et al. 2012). This deletion is often followed by overrepresentation of 3q and 
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precedes other chromosomal alterations such as deletions of 5q, 9p and 17p 
(Wistuba et al. 1999; Swarts et al. 2012). Putative tumour suppressors located at 
chromosome 3p are identified in four separated areas, including 3p12-13 (DUTT1, 
ROBO1), 3p14.2 (FHIT), 3p21.3 (BAP1, CTNNB1, FUS1, HYAL2, MLH1, RASSF1A, 
SEMA3B, SEMA3F) and 3p24.6 (VLH, RARB) (Zienolddiny et al. 2001; Wistuba and 
Gazdar 2006; Swarts et al. 2012). Additionally, RARB (in approximately 50%) and 
RASSF1A (in approximately 85%) are frequently methylated in SCLCs but less often 
in carcinoids (Toyooka et al. 2001).  
Deletion of 11q is the most frequently observed alteration in pulmonary carcinoids; its 
telomeric portion is associated with AC and is an important prognostic factor for these 
tumours, representing a marker of tumour progression rather than initiation of 
tumorigenesis (Swarts et al. 2011; Swarts et al. 2012). Deletion of 11q is the only 
chromosomal aberration with comparable frequency in carcinoids (28%) and 
neuroendocrine carcinomas (32%) (Swarts et al. 2012). These deletions are mostly 
centred around regions with a high density of genes (11p13, 11p22, 11p23, 11p24), 
and only in few cases could a deletion of the whole chromosome arm be observed 
(Koreth et al. 1999). Tumour suppressor genes identified in these regions include 
ADAMTS8 (11q24.3), ATM and TSLC1 (11q22.3), SDHD (11q23.1) and particularly 
the MEN1 gene encoding menin (11q13). 
Menin, a complex tumour suppressor protein with many different functions in multiple 
pathways, is responsible for the familial hereditary syndrome multiple endocrine 
neoplasia type 1 (MEN1-syndrome). Patients with MEN1-syndrome have inherited 
mutations of the MEN1 gene, predisposing them to the formation of multiple NETs, 
including bronchial carcinoids (Swarts et al. 2012). In contrast, neither SCLCs nor 
LCNECs have been reported to develop in association with MEN1-syndrome 
(Sachithanandan et al. 2005). The frequency of sporadic lung carcinoids that actually 
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display MEN1 gene mutations is approximately 18%, but the percentage of loss-of-
heterozygosity LOH of the MEN1 region at chromosome 11q13 is nearly 36% 
(Swarts et al. 2012). Importantly, MEN1 mutations are largely absent from sporadic 
neuroendocrine lung carcinomas (Debelenko et al. 2000; Swarts et al. 2012). 
The other important shared genomic alteration between pulmonary carcinoids and 
high-grade tumours are deletions on chromosome 13q, although they appear in 
much higher frequencies in the high-grade group (Swarts et al. 2012). The most 
important tumour suppressor genes located at this region are RB1 (13q14), BRCA2 
(13q12.3) and ING1 (13q34). 
 
Table 3 Molecular characteristics that distinguish lung carcinoids from SCLC (Swarts et al. 
2012). 
Molecular Characteristic Carcinoids SCLC Relation to Smoking 
Number of chromosomal 
alterations 3.8 14.4 Yes 
Chromosomal instability Rare Frequent Yes 
Telomerase activity 7% (TCs) 93% Unknown 
3p loss 10% 92% Yes 
FHIT protein expression 100% 0% Yes 
4q loss 5% 79% Unknown 
5q loss 4% 79% Yes 
13q loss 14% 83% Yes 
pRb downregulation 9-21% (TC-AC) 90% Unknown 
17p loss 7% 73% Yes 
p53 mutation 6% 90% Yes 
p53 upregulation < 10% > 50% Yes 
Bcl-2:Bax ratio> 1 5% 90% Unknown 
CASP8 methylation 18% 41% Unknown 
Β-Catenin dislocation 11-41% 90-93% Unknown 
E-Cadherin dislocation 17-46% 67-90% Yes 
CDH1 methylation ~ 25% ~ 60% Unknown 
Fascin protein expression < 35% 100% Unknown 
Snail protein expression Weak Strong Probably 
Ki67 proliferative index < 5% > 25% Unknown 
Cyclin B1 protein overexpression 4% 84% Unknown 
c-Kit protein expression 11% 56% Unknown 
MEN1 mutation 18-36% 0% Unknown 
NCAM1-PSA protein expression 53% 95% Unknown 
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Gene Expression Profiles 
Only a limited number of studies describe genome-wide expression profiling of 
pulmonary neuroendocrine tumours including carcinoids (Anbazhagan et al. 1999; 
Bhattacharjee et al. 2001; Virtanen et al. 2002; He et al. 2004; Jones et al. 2004; 
Swarts et al. 2012). There are only a few genes that have been consistently reported 
to show a differential expression between carcinoids, LCNECs and/or SCLCs, 
respectively. The findings in these studies show that carcinoid tumours and high-
grade NETs share only a few overlapping genetic alterations, while a distinct group of 
genes are specifically associated with these two groups. Moreover, SCLCs and 
LCNECs cluster separately, but more closely to each other than to carcinoid tumours. 
Bhattacharjee et al. showed that SCLCs and carcinoids shared high-level expression 
of neuroendocrine genes such as INSM1, ASCL1 and CHGA (Bhattacharjee et al. 
2001; Swarts et al. 2012). In contrast, another study observed low frequencies of 
ASCL1 expression in TCs compared to high-grade NETs of the lung (Jiang et al. 
2004). Immunohistochemistry for CHGA has been reported as being positive in a 
higher frequency in carcinoids than in poorly differentiated neuroendocrine lung 
tumours (Lantuejoul et al. 1998). While NCAM1 has been reported as being 
overexpressed in both SCLC and carcinoids (Jones et al. 2004; Swarts et al. 2012), 
several immunohistochemical studies showed that the NCAM-PSA variant was more 
often present in SCLCs (95.2%) than in pulmonary carcinoids (52.8%) (Kibbelaar et 
al. 1989; Komminoth et al. 1991; Michalides et al. 1994; Patriarca et al. 1997; 
Lantuejoul et al. 1998). While the majority of LCNECs have been reported as being 
positive for this variant, ACs show variable frequencies of positivity (Michalides et al. 
1994; Patriarca et al. 1997; Swarts et al. 2012). 
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Tumour Suppressors and Oncogenes 
Several tumour suppressor genes and oncogenes have been related to pulmonary 
tumorigenesis, including Bcl-2 family members, CDH1, FHIT and TP53 (Swarts et al. 
2012).  
The protein expression levels of p53, the mutation frequencies of the TP53 gene and 
the percentage of LOH at the TP53 locus differ greatly between lung carcinoids and 
high-grade neuroendocrine lung tumours (Swarts et al. 2012). Mutations of TP53 are 
reported to be rare or absent in lung carcinoids (Lohmann et al. 1993; Przygodzki et 
al. 1996; Couce et al. 1999), but are present in up to 90% of high-grade NETs 
(Leotlela et al. 2003; Swarts et al. 2012). Also the frequency of LOH rises 
considerably from carcinoids towards neuroendocrine carcinomas (Onuki et al. 
1999). Similarly, there is a significant increase in p53 expression, indicating a TP53 
mutation, when comparing carcinoids to lung carcinomas (Brambilla et al. 1996; 
Swarts et al. 2012). In addition, alterations of the p53 main regulator Mdm2 may be 
involved; 30% of neuroendocrine lung tumours show overexpression of this gene 
(Eymin et al. 2002). 
Epithelial to mesenchymal transition is characterized by decreased CDH1 expression 
and increased expression of tyrosine kinase receptors, including EGFR, FGFR and 
IGFR (Swarts et al. 2012). CDH1 interacts with CTNNB1, a main transducer of Wnt-
signalling to the nucleus. CDH1 is expressed in most NETs and CTNNB1 in all lung 
NETs, although a disruption of normal membrane associated expression of these 
proteins has been observed (Salon et al. 2004; Pelosi et al. 2005; Swarts et al. 
2012). This dislocation to the cytoplasm gradually increases in both frequency and 
severity from low-grade TCs to high-grade SCLCs. 
The pRb pathway is altered significantly more often in high-grade NETs than in 
carcinoids. In general, pRb protein expression is gradually lost when comparing 
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tumours with a higher differentiation with poorly differentiated NETs (Swarts et al. 
2011; Swarts et al. 2012). Also LOH at 13q14.2 appears approximately three times 
more frequently in high-grade neuroendocrine lung tumours than in pulmonary 
carcinoids (Onuki et al. 1999). 
Pulmonary carcinoids need to expand, although these tumours show a very low 
proliferation rate. However, the intrinsic apoptosis pathway, including BCL2, BCL2L1 
(Bcl-X) and BAX family genes, is more often inhibited in high-grade pulmonary NETs 
in comparison to carcinoids, and SCLCs in particular display very low apoptotic 
indices (Brambilla et al. 1996; Swarts et al. 2012). LCNECs show high (1-7%) 
apoptotic indices compared to SCLCs (<0.1%) (Brambilla et al. 1996; Swarts et al. 
2012). Furthermore, an inversion in the Bax/Bcl-2 ratio towards cell survival (Bcl-2) in 
high-grade lung NETs has been reported, e.g., 90% in SCLCs compared to 5% in 
carcinoids (Brambilla et al. 1996; Swarts et al. 2012). Other studies showed 
comparable results, with an almost intact intrinsic apoptotic pathway in TCs, a 
moderately affected pathway in ACs and a largely disordered pathway in the high-
grade NELCs (Swarts et al. 2012). Similar to expression of mutant p53, upregulation 
of Bcl-2 and downregulation of Bax, resulting in an inverted Bax/Bcl-2 ratio was 
observed in preneoplastic lesions adjacent to lung cancers (Brambilla et al. 1998; 
Gosney et al. 2011; Swarts et al. 2012). 
 
1.6 Applied Detection Methods 
A common and cost-effective method for long-term storage of tissues in the 
pathological routine diagnostic is formalin-fixation followed by paraffin embedding 
(FFPE). These FFPE tissues are the most prominent source of nucleic acids in 
pathological laboratories. This procedure makes it possible to connect the genetic 
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information of the samples with their clinical follow-up data and therefore provide the 
requirements for large-scale retrospective studies with extensive patient collectives.  
During the fixation process, chemical modifications such as crosslinking and 
oxidative deamination of the nucleic acids occur, decreasing the reliability of the 
material for molecular biological analysis (Ibusuki et al. 2011). In addition, storage 
conditions like temperature, exposition to ultraviolet light and oxygen exposure affect 
the integrity of the nucleic acids (von Ahlfen et al. 2007; Ludyga et al. 2012). This led 
to intense discussions about FFPE material as a source for DNA and RNA, but 
recent studies have shown that FFPE can be used for reliable DNA and RNA 
investigations (von Ahlfen et al. 2007; Walter et al. 2013).  
 
miRNA expression profiles can be screened in a broad manner through different 
methodical approaches, such as next generation sequencing (NGS), microarray 
hybridizations or quantitative polymerase chain reaction (qPCR) based screening 
methods.  
Quantitative real-time PCR correlates exonuclease digestion-induced increase of 
fluorescence, triggered by the Förster resonance energy transfer (FRET) effect, with 
the initial quantity of nucleic acids of a specific target in the measured sample. 
Therefore, specific systems using probes (e.g., TaqMan® probes) complementary to 
the region of interest (ROI) are used. These probes are labelled with both a 
fluorophore (reporter) for detection and its counterpart fluorophore (quencher) 
proximate to each other to induce FRET. Digestion via the 5’ – 3’ exonuclease 
activity of the DNA-polymerase used leads to separation of the two fluorophores and 
therefore to the loss of FRET, resulting in measurable laser-induced fluorescence of 
the reporter fluorophore. 
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An additional problem caused by the small size of miRNA-molecules is the synthesis 
of the cDNA necessary for subsequent amplification. These cDNA-molecules have to 
be long enough to provide the space for hybridization of at least one primer and the 
real-time probe. Due to the short length of miRNA nucleotide sequences, normal 
cDNA-synthesis is not feasible for this application; a special, looped reverse 
transcriptase primer is needed. The additional loop structure elongates the miRNA-
cDNA amplicon to a sufficient length during this process.   
 
The NanoString nCounter technology is a robust, fast and reproducible technique 
with low costs enabling the detection of multiple molecular markers simultaneously 
(Geiss et al. 2008). A non-enzymatic, multiple sequence-specific probe assay is used 
to assess the number of targeted molecules. A capture probe tagged with biotin and 
a reporter probe with specific fluorescent dyes hybridise specifically to the target 
molecule. Each reporter probe contains a sequence-specific barcode labelled with six 
different fluorescent dyes. Excess probes are removed and the biotin of the capture 
probe is linked to streptavidin on a surface. All molecules are arranged in one 
direction to prevent false assignment. The fluorescent dyes are excited by a laser 
and photographic images are taken. The quantity of the detected barcodes is equal 
to the amount of molecules. Since there are many sequence-specific barcodes 
available, the method could be used for an 800-plex application. Measuring reference 
genes allows a relative quantification to determine gene expression. Personalized or 
standard probe sets are available, allowing customized application of the method. 
The beneficial feature of this colour-coded barcode technology is its repeatable 
measurement ability. Even though the fluorescent signal fades after each laser 
induction, the barcode sequence is still the same. This technology allows gene 
expression analysis, miRNA assessment and copy number variation (CNV) analysis 
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in a highly professional way, making it a superior method for validating results or 
even as a  principal research method (Northcott et al. 2012). 
 
Due to the increasing number of genetic variations relevant for prediction of 
therapeutic success of modern anti-cancer therapies, new sequencing methods are 
necessary to analyse multiple targets and/or samples simultaneously in a time- and 
cost-effective manner, thus resulting in the development of different NGS-platforms. 
Despite all the differences between these platforms, they all share the properties of 
analysing clonally amplified molecules. This results in an additional quantitative 
assessment of mutated alleles, even within an extensive wildtype 
background (Vollbrecht et al. 2013). To reach such sensitivity with conventional 
sequencing methods like Sanger, special preparation protocols like the COLD-PCR 
would be necessary (Mairinger et al. 2014). 
During conventional Sanger or pyrosequencing, the ROI contained within the entire 
sample gets amplified. The measured signal represents the whole population. For 
NGS, individual nucleic acid molecules are immobilised and separated on a surface. 
Afterwards, these single spots, also called ‘clusters’, are clonally amplified directly at 
this spot and then sequenced in parallel. Therefore, the measured signal for each 
cluster represents a single allele; the sum of all clusters originating from one ROI 
represents the whole population of alleles in the proper stochastic proportion. The 
sequencing methods differ from platform to platform and range from sequencing by 
synthesis using removable terminators (MiSeq, Illumina, San Diego, CA, USA) and 
pyrosequencing (454, Roche Applied Sciences, Penzberg, Germany) to sequencing 
by ligases (SOLiD, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and 
physical sequencing using semiconductors (Ion Torrent, Thermo Fisher Scientific). 
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Some of these high-throughput sequencing methods need masses of input material 
(e.g. 250ng gDNA for MiSeq TruSeq library preparation); however, preamplification 
methods like isothermal multiple displacement amplification (IMDA) can solve such 
problems for daily routine applications (Mairinger FD 2014). 
Table 4 gives a technical summary of the detection methods used. 
 
Table 4 Comparison of the different high-throughput methods used 
Method 
NanoString 
nCounter 
TaqMan Array Human 
MicroRNA Cards 
Illumina MiSeq 
Input Material DNA; RNA RNA DNA; RNA 
Capacity 800-plex 759-plex 2-8 Gigabases 
Sample 
preparation 
none cDNA synthesis Bridge-PCR 
Preparation 
duration 
15 minutes-2 
hours 
≥ 2 hours 2 days - 1 week 
Process duration 2 days 1.5 hours 1 day 
 
1.7 Aims  
Both pulmonary carcinoids and SCLCs have been previously reported to arise from 
serotonin producing Kulchitsky-type cells, currently known as pulmonary 
neuroendocrine cells (PNECs), which are the first cells to differentiate in the 
epithelium during lung development (Bensch et al. 1968; Warburton et al. 2000; 
Swarts et al. 2012). Nevertheless, lung carcinoids and high-grade neuroendocrine 
lung carcinomas show a very different clinical outcome, with a five-year overall 
survival of 92-100% for TCs and 61-88% for ACs, compared to 13-57% for LCNECs 
and 5% for SCLCs (Rossi et al. 2005; Travis 2010). Morphological differences 
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classify them as at least three different entities, termed carcinoids, LCNECs and 
SCLCs.  
 
The studies summarized in this dissertation were conducted to examine whether 
neuroendocrine tumours of the lung are a distinct entity with different forms of 
differentiation or are different independent tumour entities. These tumours were also 
screened for possible biomarkers useful for diagnostic purposes, improving the 
current diagnostic tools and prognostic factors in this subset of tumours and 
potentially predicting the response to different chemotherapeutic regimes and small-
molecule inhibitors for targeted tumour therapy. 
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2. Material and Methods 
2.1 Patient Collective 
Two hundred-one patient samples of primary pulmonary neuroendocrine tumours 
were collected including atypical and typical carcinoids as well as LCNEC and SCLC. 
All samples were resected between 2005 and 2012 at the Ruhrlandklinik, West 
German Lung Centre of the University Hospital Essen, Essen (NRW, Germany). 
Patient samples were recruited from the biobank-database of the Institute of 
Pathology of the University Hospital Essen (NRW, Germany). All samples were 
formalin-fixed and paraffin embedded (FFPE). A reevaluation of all samples was 
done by two experienced pathologists. Out of this collective, the 80 most 
representative specimens were used for all further analysis. Inclusion criteria were 
sufficient tumour material and a minimum of contamination by non-tumorous 
lymphocytic and stromal cells. The complete clinical data set and all IHC and qPCR-
based parameters determined for diagnostic purposes were collected.  
 
The collective encompassed 107 male and 94 female patients. The patients’ age at 
time of diagnosis ranged from 19 to 85 years (median: 61; mean: 60). Forty-six 
patients were suffering from TC, 26 from AC, 57 from LCNEC and 72 from SCLC. 
TNM staging was performed according to the WHO classification guidelines (Travis 
et al. 2004). Forty-two tumours were classified as pT1, eleven as pT1a, three as 
pT1b, 38 as pT2, five as pT3, five as pT4 and two as pTX with no conclusive 
classification of the pathological stage. The evaluation of tumour grade showed 52 
G1, 17 G2, 61 G3 and 47 G4 tumours. Lymph node status (N) was finally determined 
in 130 cases (87 pN0, 23 pN1, 17 pN2, 3 pN3) as well as the distant-metastasis 
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status (M) in all cases (191 M0 and 10 M1). Blood vessel (V) and lymph node status 
(L) could be conclusively clarified in 109 cases, 11 V1 and 16 L1 infiltrations could be 
found. 
Follow up was collected in 75 cases. 36 were already deceased at the time of data 
collection. Clinical follow-up data concerning disease progression could be collected 
from 47 patients. Seventy-three of them showed progressive disease (PD), six stable 
disease (SD) and four partial remission (PR).  
Additionally, 20 non-tumorous lung tissues obtained from resections in patients with 
pneumothorax were used as benign tissue controls. These 20 samples were 
recruited from the Department of Pathology, Helios Klinikum Emil von Behring, Berlin 
(Berlin, Germany), and were evaluated by an experienced pathologist (PD. Dr. T. 
Mairinger). Only samples without an inflammatory reaction served as normal controls. 
. 
2.2 Study Design 
The studies included in this doctoral thesis were designed to clarify, whether 
pulmonary neuroendocrine tumours form one distinct group of tumours or have to be 
considered as different independent entities.  
In order to address this question, 74 representative tumour specimens were used for 
sequencing analysis including TC, AC, LCNEC and SCLC. Sequencing was 
performed on a MiSeq instrument (Illumina, San Diego, CA, USA) using the TruSeq 
sequencing-chemistry (Illumina). A commercially available primer-pool covering the 
221 most important mutation hotspots related to human malignant neoplasias was 
used (TruSeq Amplicon Cancer Panel, Illumina). 
Additionally, mRNA-expression profiles of 80 tumour samples were determined. 
Measurement of mRNA profiles of 91 selected genes was performed by the 
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NanoString nCounter technology (NanoString Inc., Seattle, US). The majority of 
these patient samples is in concordance with the specimens used for SNP 
genotyping. These 91 genes include the most important regulators of angiogenesis, 
apoptosis, cell cycle regulation, DNA-repair mechanisms, folic acid metabolism, 
growth factor signalling, MET downstream signalling, MTOR pathway regulation, 
neuroendocrine differentiation, SOX signalling and tumour environment.  
Three unequivocal samples of each tumour entity were chosen to be tested for their 
miRNA signature by 384 well TaqMan low-density array real-time qPCR. Special 
inclusion criteria for this analysis were well differentiated cells, high content of tumour 
tissue and a for each entity representative clinical course. Analysis were performed 
using the TaqMan Array Human MicroRNA Card A and TaqMan Array Human 
MicroRNA Card B v3.0 (both Applied Biosystems), respectively. These cards contain 
primer sets for 759 of the believed most important and most investigated miRNA 
species.  
Finally, the same pulmonary neuroendocrine tumour samples were analysed via 
TaqMan qPCR (Applied Biosystems) for expression of the five most important 
subunits of the 26S proteasome. 
 
The investigations conform to the principles outlined in the declaration of Helsinki and 
were approved by the ethical committee of the University Hospital of Essen (ID: 13-
5382-BO) and for the patients from Berlin, used for control-purposes, informed 
consent was obtained. 
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2.3 Parallel Sequencing by Synthesis 
Procedure and Panel Design 
Sample preparation was done using the TruSeq Amplicon - Cancer Panel (Illumina 
Inc., San Diego, CA, USA) followed by sequencing on the MiSeq Personal 
Sequencer (Illumina) according the protocols provided by the manufacturer. The 
Cancer Panel covers 48 tumour-relevant genes including 221 mutation hotspots. The 
list of these genes is summarised in table 5. 
 
Table 5 Summary of investigated genes provided by the TruSeq Amplicon-Cancer Panel. 
ABL1 AKT1 ALK APC ATM BRAF CDH1 CDKN2A 
CSF1R CTNNB1 EGFR ERBB2 ERBB4 FBXW7 FGFR1 FGFR2 
FGFR3 FLT3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 
JAK2 JAK3 KDR KIT KRAS MET MLH1 MPL 
NOTCH1 NPM1 NRAS PDGFRA PIK3CA PTEN PTPN11 RB1 
RET SMAD4 SMARCB1 SMO SRC STK11 TP53 VHL 
 
DNA Extraction and Library Preparation 
For DNA-isolation FFPE tissue was used. Tumour tissue blocks were cut by a 
microtome Cool Cut HM 355S (MICROM International, Walldorf, Germany) to 
generate 4 µm thick slides. Three to five paraffin tissue slides per sample were 
deparaffinised with xylene prior to DNA extraction. Genomic DNA was isolated via 
Maxwell® 16 Research (Promega Corporation, Madison, USA) as recommended by 
the manufacturer. Subsequently, DNA quantification was performed by using the 
Nanodrop ND-1000 (PEQLAB Biotechnologie GmbH, Erlangen, Germany) and Qubit 
2.0 (Life Technologies, Carlsbad, USA). Samples of isolated gDNA were prepared 
according to the TrueSeq Custom Amplicon – Library Preparation guide. Prior 
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sequencing, constructed library pools were denaturised with NaOH leading to a final 
concentration of 8 mM NaOH. Additionally, a TruSeq Cancer Amplicon (TSCA)-
control was spiked into each library pool. A Sample Sheet was created with the 
Illumina Experiment Manager software (Illumina). 
 
Library Construction and Sequencing 
Paired-end sequencing (2x 150 base-pairs, 302 cycles in total) was performed with 
eight index reads and MiSeq v2 chemistry.  Each cartridge (300 cycles, Illumina) was 
loaded with a library pools containing 23 or 24 samples and control DNA (TrueSeq 
Control Amplicon (TSCA), Illumina) to achieve a calculative mean coverage of 800-
1000x. 
 
Alignment of Raw Reads and Preliminary Analysis 
FastQ-files were generated by the MiSeq reporter software and data sets were 
aligned against the human genome (Hg19). For analysis of the aligned reads 
including variant calling, the software Avadis NGS (Strand Scientific Intelligence, 
California, USA) was used. Reads with a quality score < 30 were discarded by the 
used algorithm. Detected nucleotide changes were checked for known variants using 
the db135SNP database. Additionally data filtering was done by excluding variants 
with less than 25 effective reads (total reads*(percent variant reads/100)) or below 
10% variant reads. Afterwards, synonymous variants were removed. The samples 
were subdivided into tumour types and for every investigated gene a basic statistical 
analysis was done (sum and mean value of mutations and sum, mean value and 
frequency of variants for every tumour entity, respectively).  
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2.4 Gene Expression Profiling by NanoString Technology 
RNA Extraction and RNA Integrity Assessment 
Three to five paraffin sections per sample were deparaffinised with xylene prior to 
RNA extraction using the miRNeasy FFPE kit (Qiagen, Hilden Germany) as 
recommended by the manufacturer, using adapted times and volumes (e.g. overnight 
digestion). RNA concentration was measured using a Nanodrop 1000 instrument 
(Nanodrop, PEQLab Biotechnologie GmbH, Erlangen, Germany). RNA integrity was 
assessed via RIN-values using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, 
CA, US) at the NanoString nCounter Core Facility at the University of Heidelberg, 
Germany. Smear analysis was performed using the Agilent 2100 expert software to 
determine the proportion of RNA ≥300 nucleotides within a given sample. 
RNA not immediately used was stored at –20°C until use. 
 
NanoString CodeSet Design and Expression Quantification 
Important genes of different tumour pathways and genes involved in neuroendocrine 
differentiation were included in the custom CodeSet. The CodeSet was designed to 
consist of a total of 91 genes with different signature genes for each subgroup. 
Investigated genes and corresponding pathways are summarised as follows: SOX 
signalling (MYB, MYBBP1A, OCT-4, PAX6, PCDHB, RBP1, SDCBP, SOX2, SOX4, 
SOX11, TEAD2); MET pathway (GAB1, GRB2, MET, MST1R, PAX5); MTOR 
signalling (MTOR, RHOA, RICTOR, RPTOR); angiogenesis (CRHR2, FIGF, FLT4, 
HIF1A, KDR, MMP3); apoptosis (ASCL1, BAX, BCL2, CASP-8, CASP-10, FAS, 
MDM2, TP53, PNN); neuroendocrine differentiation (CHGA, GABBR2, NCAM1, NTS, 
RTN1, SEMA3B, SYP); folate metabolism (ATIC, DHFR, FOLR1, FPGS, GART, 
GGT1, SLC19A1, TYMS); DNA-repair (ERCC1, MLH1, MSH2, MSH6, XRCC1); cell 
cycle regulation (CCND1, CCNE1, CDK1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, 
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CDKN2A, MIB-1); tumour environment  (LDHA, LDHB, LDHC, MAN2A1, MAN2B1, 
MAN2C1, TKTL1); growth factors (GF), GF-receptors and downstream signalling 
(IGF-1, IGF-2, MET, EGFR, FGFR1, AKT1, ALK, PTEN) and miscellaneous (CAT, 
CYP1A1, FN1, MDM2, NES, NKX21, TP53; SOD1, STK11, TWSG1, UCHL1). Three 
reference genes (ACTB, GAPDH, and HPRT1) were also included in the CodeSet for 
biological normalisation purposes. Probe sets for each gene in the CodeSet were 
designed and synthesised by NanoString Technologies. All designed Probe Sets 
were re-evaluated using the BLAST-Algorithm (Basic Local Alignment Search Tool). 
An overview of all targets is given in table 6. 
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Table 6 Summary of investigated genes involved in different pathways or cellular 
mechanisms. 
Cellular mechanism Gene 
Angiogenesis CRHR2, FIGF, FLT4, HIF1A, KDR, MMP3 
Apoptosis ASCL1, BAX, BCL2, CASP-8, CASP-10, FAS, MDM2, 
TP53, PNN 
Cell cycle regulation CCND1, CCNE1, CDK1, CDK2, CDK4, CDK6, CDKN1A, 
CDKN1B, CDKN2A, MIB-1 
DNA-repair ERCC1, MLH1, MSH2, MSH6, XRCC1  
Folate metabolism ATIC, DHFR, FOLR1, FPGS, GART, GGT1, SLC19A1, 
TYMS 
Growth factors (GF), GF-receptors 
and downstream signalling 
IGF-1, IGF-2, MET, EGFR, FGFR1, AKT1, ALK, PTEN 
Reference genes ACTB, GAPDH, HPRT1 
MET pathway GAB1, GRB2, MET, MST1R, PAX5 
Miscellaneous CAT, CYP1A1, FN1, NES, NKX21, SOD1, STK11, 
TWSG1, UCHL1 
MTOR signalling MTOR, RHOA, RICTOR, RPTOR 
Neuroendocrine differentiation CHGA, GABBR2, NCAM1, NTS, RTN1, SEMA3B, SYP 
SOX signalling MYB, MYBBP1A, OCT-4, PAX6, PCDHB, RBP1, SDCBP, 
SOX2, SOX4, SOX11, TEAD2 
Tumour environment LDHA, LDHB, LDHC, MAN2A1, MAN2B1, MAN2C1, 
TKTL1 
 
Total RNA (100 ng) including miRNAs originating from FFPE material was hybridised 
overnight and afterwards analysed on the DigitalAnalyzer (NanoString).  
 
NanoString Data Processing  
Raw NanoString counts for each gene were subjected to a technical normalisation 
using the counts obtained for positive control probe sets prior to a biological 
normalisation using the three reference genes included in the CodeSet.  
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2.5 TaqMan® Array Human MicroRNA Cards  
RNA Extraction and RNA Integrity Assessment 
For details according to the RNA extraction and RNA integrity assessment please 
refer to 2.4. 
 
cDNA Synthesis and Preamplification 
For cDNA synthesis the Megaplex RT Human Primer Pools A and B (Applied 
Biosystems, Foster City, CA, USA) in combination with the TaqMan miRNA Reverse 
Transcription Kit (Applied Biosystems) were used. cDNA not immediately used was 
stored at -20°C. Preamplification was also conducted with Megaplex Preamplification 
Primer Pools A and B (Applied Biosystems) in combination with the TaqMan miRNA 
Preamplification Kit (Applied Biosystems). Preamplified samples were stored at -
20°C until usage.  
 
TaqMan real-time qPCR for miRNA Expression Determination 
For 384 well TaqMan low-density array real-time qPCR, preamplification products 
were pressed through microchannels into wells fixed in the card, preloaded with 
immobilised, dehydrated target-specific primer-probe pairs. PCR analysis was run on 
the ABI PRISM 7900 System. Analysis was done with TaqMan Array Human 
MicroRNA Card A and TaqMan Array Human MicroRNA Card B v3.0 (both Applied 
Biosystems), respectively. Quantitative PCR was performed using the ready-to-use 
TaqMan Universal PCR Master Mix (Applied Biosystems). Of note, qPCR analysis 
was performed in concordance to the MIQE-guidelines (Bustin et al. 2009). 
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Bioinformatical Data Analysis 
miRNA target-sites were descriptively determined using the miRanda-database 
(miRanda), inhibition scores were calculated by the mirSVR algorithm. The ten most 
differentially regulated miRNA-targets in the various neuroendocrine tumours were 
selected for further analysis. In addition, all targets with a score higher than 2.00 
were selected for the identification of possibly deregulated pathways. Associated 
pathways, which were affected by differences in the miRNA expression levels, were 
discovered and, if possible, correlated to gene- and protein expression levels 
available. Additionally, a gene ontology (GO)-term analysis to classify differentially 
regulated biological processes was performed. 
Databases used for pathway identification were uniprot.org and the NCBI website 
gene-search and BioSystems-search, respectively. 
 
2.6 Determination of 26S-Proteasome Genexpression via qPCR 
The subunits α1 and α5, β4 and β5 (PSMA1, PSMA5, PSMB4, PSMB5 ) as well as 
δ1, also known as RPN2, which is part of the proteasome capping structure, of the 
26S-Proteasome were investigated. To evaluate the expression levels of the subunits 
of the 26S proteasome in the pulmonary neuroendocrine tumours, TaqMan real-time 
qPCR was applied. Twenty samples of each entity as well as 20 benign samples 
represented by spontaneous pneumothorax tissue of otherwise healthy patients were 
analysed. 
 
RNA Extraction and RNA Integrity Assessment 
For details according to the RNA extraction and RNA integrity assessment please 
refer to 2.4. 
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cDNA Synthesis 
For cDNA synthesis the “iScript Select cDNA Synthesis Kit” (BioRad, Hercules, CA, 
USA) was used. cDNA synthesis was done with the total RNA-samples. cDNA not 
immediately used was stored at –20°C. Ct-values were normalised to the mean of 
two different endogenous reference genes, namely β-actin (ACTB) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
 
TaqMan real-time qPCR Analysis 
Relative cDNA quantification of PSMA1, PSMA5, PSMB4, PSMB5 and PSMD1 and 
two reference genes (GAPDH and ACTB) as internal reference for biological 
normalisation were measured. For qPCR, commercial TaqMan® Gene Expression-
assays (Applied Biosystems®, AoD, Assay-ID: Hs03023943-g1, Hs01027362-g1, 
Hs00932059-m1, Hs01123843-g1, Hs01002826-g1, Hs00160631-m1) with optimised 
primer and probe concentrations were used. 10µl was sufficient as total reaction 
volume. The AoD were chosen because of their short amplicon size (90 to 110bp) to 
overcome FFPE-specific problems and additionally, they spanned exon-exon 
boundaries. Each target was measured in triplicate. 
For assay validation, standard curves were calculated using six different 
concentrations of a pool out of all isolated RNAs. Calculation was performed 
automatically with the Roche® LightCycler® 480 II data analysis program.  
qPCR analysis was performed in concordance to the MIQE-guidelines (Bustin et al. 
2009). 
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Preliminary Data Analysis 
qPCR and determination of Ct-values was performed on a Roche® LightCycler® 480 
II. Ct-values were calculated by the fit-points method. For consecutive statistical 
analysis, 2-ΔΔCt values were calculated in relation to the benign control samples. 
 
2.7 Immunohistochemistry 
For immunohistochemical characterisation staining of whole tissue slides with 
antibodies directed against Pan-Cytokeratin (DAKO, Clone MNF116, Hamburg, 
Germany), CD56 (Zytomed, clone RCD56, Berlin, Germany), ChromA (Novocastra, 
clone 5H7, Wetzlar, Germany) and TTF-1 (DAKO, Clone 8G7G3/1, Hamburg, 
Germany) was performed. The proliferation index was determined by staining with 
antibodies directed against the proliferation associated marker Ki67 (Zytomed, clone 
K-2, Berlin, Germany) using a fully automated stainer (Dako AutostainerPlus, 
Copenhagen, Denmark). Apoptosis was determined by IHC against cleaved caspase 
3 (Cell Signalling, Beverly, MA, USA). 26S-Proteasome expression was determined 
by IHC directed against PSMB4 (Sigma Aldrich, polyclonal antibody, Taufkirchen, 
Germany). 
An overview of the different pretreatment protocols and the dilution factors is given in 
Table 7. 
 
 
 
46 
Table 7 Pretreatment protocols and dilutions of the different used antibodies  
Company Target Clone Temperature pH Pretreatment Incubation Dilution 
DAKO Pan-Cytokeratin  MNF116 37°C - 4’ Pronase 30’ 1:1000 
Zytomed NCAM RCD56 98°C 6.0 30’ Citrate 30’ 1:1000 
Novocastra CHGA 5H7 98°C 6.0 20’ Citrate 30’ 1:100 
DAKO TTF1 8G7G3/1 30°C 9.0 20’ EDTA 30’ 1:1000 
Zytomed TKI67 K-2 98°C 6.0 30’ Citrate 30’ 1:2000 
Cell Signalling CASP3 polyclonal 98°C 6.0 20’ Citrate 60’ 1:100 
Sigma Aldrich PSMB4  polyclonal 30°C 9.0 20’EDTA 60’ 1:20 
 
Preliminary Data Analysis 
The immunoexpression of Ki67 was quantified by applying an internally evaluated 
four stage score (0= 0%, 1 ≤10%, 2 = 11 - 50%, 3 ≥ 50% stained cells), whereas 
cleaved caspase was scored by a different system (0 = 0%, 1 ≤ 5%, 2 = 5-10%, 3 ≥ 
10%).  
Pan-Cytokeratin, CD56 (NCAM1), CHGA and TTF1 immunohistochemistry was 
determined just by presence (positive) or absence (negative). For PSMB4 
immunohistochemical expression, the H-Score was first preferred. Due to the 
universal and strong staining of all tumours against PSMB4, also its expression was 
determined in a dichotomous way.  
 
2.8 Statistical Analysis 
To determine a correlation between affected genes and clinical parameters, the R 
statistical software environment (The R Foundation for Statistical Computing, Institute 
for Statistics and Mathematics, Vienna, Austria; v2.15.2) was used. Correlation 
analysis was performed with a customized algorithm for the R software.  
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The exact Wilcoxon Mann-Whitney Rank Sum test was used to test associations 
between miRNA expression and dichotomous variables (e.g., gender). For the 
analysis of possible associations between miRNA and clinical variables (age, age of 
blocks, etc.), a Spearman’s rank correlation test was performed. Additionally, 
Spearman’s rank correlation test was done to test associations between tumour type 
and expression levels of different miRNAs.  
 
Similar to the analysis of miRNA-expression, association between mRNA-counts and 
2-ΔΔCt-values, respectively, and linear vectors (clinical variables) were calculated 
using the Spearman’s rank correlation rho test.  
For dichotomous features regarding gender and gene expression level, the Wilcoxon 
Mann-Whitney rank sum test was applied.  
For variables with more than two categories the Kruskal-Wallis test was performed.  
Overall survival (OS) and progression free survival (PFS) were calculated using the 
Wald-test, likelihood-ratio test and Score (logrank) test.  
 
To check correlations between protein expression levels and variables represented 
by linear vectors, the Spearman’s rank correlation rho test was chosen again. The 
Spearman’s rank correlation test was done to test associations between gene 
expression and IHC staining scores. 
The exact Wilcoxon Mann-Witney Rank Sum test was used to test associations 
between protein expression and dichotomous variables (gender).  
Survival analysis for overall and progression-free survival was done by Cox-
regression (COXPH-model), statistical significance was determined using Likelihood 
ratio test, Wald test and Score (logrank) test.  
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For illustration of the overall survival (OS) and progression-free survival (PFS), 
Kaplan-Meier curves were generated.  
 
For association analysis of the number of variants occurring in each gene and the 
tumour entity, the Kruskal-Wallis Rank Sum Test was used. The Kruskal-Wallis test 
was also used to analyse the association of mutations occurring in a gene and 
tumour type. 
Because the mutation-status of each gene leads to dichotomous factors (yes/no), 
association between genetic variants and clinical variables were calculated using the 
exact Wilcoxon Mann-Witney Rank Sum test. 
For additional dichotomous variables like patient’s gender and number of mutations 
occurring, the exact Wilcoxon Mann-Witney Rank Sum test was used.  
Correlations between linear vectors (e.g. clinical variables) and count of mutations 
were assessed by Spearman’s rank correlation rho test.  
Survival analysis for mutation-dependent overall and progression-free survival was 
done by Cox-regression (COXPH-model), statistical significance was determined 
using Likelihood ratio test, Wald test and Score (logrank) test.  
The results concerning survival were graphically illustrated by Kaplan-Meier curves. 
 
All calculated p-values were corrected by a Bonferroni-Correction for multiple testing. 
Statistical significance was assigned as p≤0.05. 
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3. Results 
miRNA Expression Profiling  
qPCR analysis was accomplished successfully in all cases. The endogenous control 
was detected between Ct 12.5 and 13.9 on both plates. All further analysis was 
performed using log(miR)-values. 
 
In the complete collective including the four entities (AC, TC, SCLC, LCNEC), 44 
miRNAs with significantly different expression were identified, eleven of them 
showing highly significant correlation with a p-value <0.01. Seven showed an inverse 
correlation to aggressiveness of the tumour (miR-22, miR-29a, miR29b, miR-29c, 
miR-367*; miR-504, miR-513C, miR-1200), the remaining a direct correlation (miR-
18a; miR-15b*, miR-335*, miR-1201). Data are summarised in Table 8. 
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Table 8 Detected significant association of miRNA expression with tumour type. Highly 
significant miRNAs are bolded. Data are presented in Figure 9 and 18. 
miRNA Tumour Type 
p-value rho 
hsa-miR-15b 0.047 0.5830 
hsa-miR-18a 0.007 0.7341 
hsa-miR-22 0.004 -0.7557 
hsa-miR-27b 0.037 -0.6046 
hsa-miR-29a 0.009 -0.7125 
hsa-miR-29b 0.009 -0.7125 
hsa-miR-29c 0.004 -0.7557 
hsa-miR-107 0.037 0.6046 
hsa-miR-125b 0.047 -0.5830 
hsa-miR-127 0.037 -0.6046 
hsa-miR-129 0.013 -0.6909 
hsa-miR-132 0.017 -0.6693 
hsa-miR-136 0.037 -0.6046 
hsa-miR-143 0.023 -0.6478 
hsa-miR-154 0.037 -0.6046 
hsa-miR-216b 0.013 0.6909 
hsa-miR-217 0.047 0.5830 
hsa-miR-328 0.023 -0.6478 
hsa-miR-338-3p 0.023 -0.6478 
hsa-miR-375 0.037 -0.6046 
hsa-miR-455 0.037 -0.6046 
hsa-miR-485-5p 0.029 -0.6262 
hsa-miR-490 0.037 -0.6046 
hsa-miR-504 0.009 -0.7125 
hsa-miR-548b-5p 0.047 -0.5830 
hsa-miR-653 0.023 -0.6478 
hsa-miR-874 0.023 -0.6478 
hsa-miR-569 0.013 -0.6909 
hsa-miR-634 0.047 -0.5830 
hsa-miR-645 0.023 0.6478 
hsa-miR-29c* 0.037 -0.6046 
hsa-miR-770-5p 0.037 -0.6046 
hsa-miR-31* 0.037 0.6046 
hsa-miR-130b* 0.029 0.6262 
hsa-miR-367* 0.003 -0.7773 
hsa-miR-15b* 0.003 0.7773 
hsa-miR-335* 0.007 0.7341 
hsa-miR-545* 0.023 0.6478 
hsa-miR-218-2* 0.047 -0.5830 
hsa-miR-513C 0.007 -0.7341 
hsa-miR-1201 0.003 0.7773 
hsa-miR-1292 0.047 0.5830 
hsa-miR-1200 0.029 -0.6262 
hsa-miR-1248 0.047 0.5830 
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miR-18a is increasing directly with more aggressive forms of the NE-tumours (from 
TC – AC – LCNEC – SCLC), showing a 100-fold higher expression in high-grade NE 
pulmonary tumours than in carcinoids, this association can also be observed for miR-
15b* and miR-335*. miR-22 expression decreases significantly more than 10-50 folds 
from typical to atypical carcinoids and LCNEC (showing an equal expression levels 
as AC) and 50-100 fold to SCLC. Furthermore, miR-29a, miR-29b and miR-29c 
expression levels decreases with increasing biological aggressiveness of the given 
neuroendocrine tumour, all showing the same expression levels in both carcinoids 
and a clear decrease regarding LCNEC and furthermore in SCLC (figure 10). miR-
504 expression seems to be constant and equal  in TC, AC and LCNEC, but is totally 
lost in SCLC. miR-367* shows a similar pattern to miR-22, but showing greater 
differences (TC/AC: approx. 1000-fold; LCNEC/SCLC: approx. 1000-fold). miR-513C 
expression can be detected in TC only and is lost or decreases to a minimal level  in 
the remaining entities. miR-1201 shows a stable level in TC and AC and an 
increased expression in high-grade NELC, and presents with higher expression in 
LCNEC than in SCLC. 
The data are depicted as boxplots in Figure 9. 
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Figure 9 Boxplots depicting significant differences in miRNA expression in neuroendocrine 
pulmonary tumours. Expression of miR-18a and miR-15b* is increasing with increasing 
malignancy of the tumour. miR-335* and miR-1201 profiles show a decreased expression in 
carcinoids compared to the neuroendocrine carcinomas. For miR-22 and miR-367* increased 
malignancy is associated with decreased expression. In SCLC, miR-504 expression is 
dramatically decreased and for miR-513C, TC show the highest expression.  
 
 
Figure 10 Boxplots showing the expression profiles of the miR-29 family displaying similar 
patterns between the different tumour entities. Decreasing expression of miR-29a-c 
correlates with increasing malignancy of the tumour. 
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For survival analysis, the COXPH-model was used. Three patients (one suffering 
from LCNEC and two suffering from SCLC) died due to cancer related reasons; none 
of the carcinoid cases had influenced the survival status of the investigated patients. 
Absolute survival time including follow-up time of censored patients ranged from less 
than one month up to more than six years.  
We identified 45 micro-RNAs to have a statistically significant impact on survival in 
our collective, determined by the Likelihood ratio test and Score (logrank) test. Nine 
of the miRNAs were highly significant in both tests (let-7d; miR-139-5p; miR-197; 
miR-301; miR-576-5p; miR-582-5p; miR-448; miR-340*; miR-1286), five showed 
statistical significance when the Wald test was applied (let-7d; miR-19; miR-576-5p; 
miR-340*; miR-1286). Data are summarised in Table 9. 
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Table 9 Calculated p-values of miRNA expression regarding OS using COXPH. Highly 
significant miRNAs are bolded; most significant miRNAs are highlighted grey. 
miRNA Overall Survival 
p-Value               
(Likelihood ratio 
test) 
p-Value                         
(Score logrank test) 
p-Value                         
(Wald test) 
hsa-let-7d 0.00665 0.06477 0.00036 
hsa-miR-10b 0.00668 0.02856 - 
hsa-miR-17 0.03828 0.04790 - 
hsa-miR-19b 0.04567 0.03092 - 
hsa-miR-20b 0.04335 0.03399 - 
hsa-miR-30c 0.01968 0.01902 - 
hsa-miR-95 0.03767 0.01995 - 
hsa-miR-106b 0.02492 0.02584 - 
hsa-miR-130b 0.04031 0.02232 - 
hsa-miR-138 0.00660 0.03985 - 
hsa-miR-139-5p 0.00660 0.00628 - 
hsa-miR-149 0.02027 0.01258 0.02581 
hsa-miR-196b 0.00660 0.03519 - 
hsa-miR-197 0.00689 0.00345 0.00317 
hsa-miR-216a 0.02496 0.03505 - 
hsa-miR-216b 0.02190 0.03537 - 
hsa-miR-301 0.00925 0.01598 - 
hsa-miR-331 0.00660 0.03736 - 
hsa-miR-340 0.03975 0.04009 - 
hsa-miR-374 0.02849 0.03736 - 
hsa-miR-454 0.02168 0.33980 - 
hsa-miR-484 0.00661 0.02801 - 
hsa-miR-525-3p 0.02521 0.04496 - 
hsa-miR-548d 0.02624 0.01665 - 
hsa-miR-576-5p 0.00828 0.01071 0.00029 
hsa-miR-582-5p 0.00660 0.00702 - 
hsa-miR-448 0.00660 0.00580 - 
hsa-miR-30a-5p 0.00662 0.01558 - 
hsa-miR-378 0.00660 0.03319 - 
hsa-miR-7* 0.00661 0.02938 - 
hsa-miR-550 0.03544 0.04218 - 
hsa-miR-454* 0.01438 0.02284 - 
hsa-miR-130b* 0.00661 0.03563 - 
hsa-miR-377* 0.01508 0.03093 - 
hsa-miR-936 0.04560 0.03846 - 
hsa-miR-340* 0.00917 0.00799 0.00198 
hsa-miR-200b* 0.00669 0.03058 - 
hsa-miR-10b* 0.00661 0.01125 - 
hsa-miR-181a-2* 0.04969 0.03275 - 
hsa-miR-106b* 0.00763 0.04640 - 
hsa-miR-1286 0.00668 0.00994 <0.00001 
hsa-miR-548M 0.02234 0.02838 - 
hsa-miR-1271 0.01600 0.04631 - 
hsa-miR-1292 0.00672 0.04997 - 
hsa-miR-1293 0.04943 0.01999 - 
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With increasing malignant biological behaviour of pulmonary neuroendocrine 
tumours, several cellular pathways are upregulated by differential expression of 
miRNAs. The pathway strongest affected is the ERK-MAPK signalling pathway. Also 
the PI3K-pathway, involved in different cellular processes, shows significant 
differences between the four tumour types of pulmonary neuroendocrine tumours. 
Furthermore, the TGF-beta pathway is becoming activated with increasing metastatic 
potential, suggesting a causal link between increased angiogenesis and 
metastasis/malignancy in pulmonary neuroendocrine tumours. In addition, the Wnt-
signalling pathway, NFkB pathway, JNK-MAPK signalling network as well as the 
MTOR-complex associated signalling is differentially regulated via miRNA expression 
in these tumours (Figure 11). 
 
 
Figure 11 Pie chart showing results of the pathway analysis in pulmonary neuroendocrine 
tumours: The pathways showing the most prominent alterations by miRNAs were shown to 
be the MAPK pathway followed by PI3K- and TGF-β-pathway. Aberrations could also be 
found for Wnt-signalling, NFB-pathway, JNK-pathway and mTOR-signalling. 
 
The GO-analysis showed 256 hits for regulation of gene expression and 
transcriptional regulation. The second major differentially regulated cellular processes 
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were cell cycle regulation (139 hits) followed by development and differentiation of 
neuronal development (134 hits). In addition, proliferation (125 hits), immune 
response (105 hits), apoptosis (96 hits) and DNA-damage response (59 hits) are 
strongly deregulated in this collective of neuroendocrine lung tumours. Furthermore, 
growth factors as well as growth-factor receptors and their pathways were observed 
to be affected (53 hits). Less significant, but also differentially regulated were the ion 
carrier-dependent uptake of compounds as well as angiogenesis (48 and 42 hits, 
respectively). Moreover, it is of note that a strongly altered regulation of the 
expression of structural cell compounds (42 hits), especially of collagens (19 hits) 
was found. The data are illustrated in Figure 12. 
 
 
Figure 12 Illustrated results of the GO analysis presenting most hits in gene expression and 
transcription. Similar hits for cell cycle and nervous system were found. Following, with 
decreasing impact, also proliferation, immune response, apoptosis, DNA-damage-response, 
growth factors and signalling, carriers, angiogenesis and expression of structural compounds 
is affected by differential miRNA expression. 
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mRNA Expression Profiling Results 
The mRNA expression analysis showed 48 significant correlations with tumour type. 
Sixteen most significant (p≤0.001), 20 highly significant (p≤0.01) and 12 significant 
(p≤0.05) candidates were identified. Most significant were BCL2, CDK6, CDKN2A, 
CHGA, FOLR1, FPGS, GAB1, MAN2C1, MLH1, PAX6, PNN, RTN1, SOX11, SOX4, 
SYP and TYMS. Highly significant values were found for ASCL1, CASP8, CAT, 
CCND1, CCNE1, CDK2, EGFR, ERCC1, FIGF, FLT4, MAN2A1, MSH6, NCAM1, 
PAX5, RBP1, RICTOR, RPTOR, SEMA3B, STK11 and UCHL1. Furthermore, the 
BCL2-BAX ratio was correlated with tumour type and showed a highly significant 
value (p=0.0064; Chi2 12.3399). The results are summarised in Table 10. 
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Table 10 Significant p-values of mRNA expression correlating with tumour type calculated by 
the Kruskal Wallis Rank Sum Test are shown. Highly significant mRNAs are bolded; most 
significant mRNAs are highlighted grey. Highlighted genes are presented in boxplots in 
Figure 13. 
mRNA vs. type p-Wert Chi2 dF 
AKT1 0.01228 10.90060 3 
ASCL1 0.00862 11.66480 3 
BCL2 0.00050 17.73310 3 
CASP8 0.00279 14.08570 3 
CAT 0.00681 12.17440 3 
CCND1 0.00179 15.02800 3 
CCNE1 0.00452 13.05300 3 
CDK1 0.01624 10.29250 3 
CDK2  0.00200 14.79270 3 
CDK6 0.00004 23.18880 3 
CDKN1A 0.03464 8.62980 3 
CDKN2A 0.00043 18.02390 3 
CHGA << 0.00001 36.81580 3 
EGFR 0.00437 13.12570 3 
ERCC1 0.00210 14.69170 3 
FGFR1 0.03008   8.94120 3 
FIGF 0.00957 11.43970 3 
FLT4 0.00539 12.67890 3 
FN1 0.02519   9.33160 3 
FOLR1 0.00001 27.16270 3 
FPGS  <<0.00001 29.24420 3 
GAB1 0.00069 17.03900 3 
GGT1 0.02889   9.03030 3 
MAN2A1 0.00537 12.68520 3 
MAN2C1 0.00051 17.67760 3 
MLH1 0.00085 16.61270 3 
MSH6 0.00644 12.29540 3 
NCAM1 0.00843 11.71320 3 
NKX21 0.01000 11.34550 3 
PAX5 0.00584 12.50620 3 
PAX6 0.00022 19.45360 3 
PNN 0.00072 16.95160 3 
PTEN 0.01641 10.26890 3 
RBP1 0.00567 12.56690 3 
RHOA 0.02677   9.19820 3 
RICTOR 0.00554 12.61750 3 
RPTOR 0.00299 13.93940 3 
RTN1 0.00070 17.03140 3 
SEMA3B 0.00597 12.45920 3 
SOD1 0.01321 10.74120 3 
SOX11 <<0.00001 28.80580 3 
SOX2 0.04982   7.82280 3 
SOX4 0.00021 19.51440 3 
STK11 0.00836 11.73170 3 
SYP  0.00005 22.54800 3 
TYMS  0.00003 23.69170 3 
UCHL1 0.00628 12.34980 3 
XRCC1 0.01312 10.75610 3 
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Furthermore, 35 significant genes correlated significantly with tumour grade. Seven 
were most significant, eight were highly significant and 20 showed significant values. 
The most significant genes were CDK6, CDKN2A, CHGA, FOLR1, SOX4, SYP and 
TYMS. As highly significant BCL2, CDK1, ERCC1, FPGS, GAB1, MAN2C1, RTN1 
and SOX11 were identified. Significant genes are summarised in Table 11.  
 
Table 11 Significant p-values of mRNA expression correlating with tumour grade calculated 
with the Spearman Test. Highly significant mRNAs are bolded; most significant mRNAs are 
highlighted grey. 
 
mRNA vs. grade p-value rho 
ALK 0.02923 -0.3217282 
ASCL1 0.03138 0.3177995 
BCL2 0.00584 0.4003202 
CASP8 0.03085 0.3187495 
CCNE1 0.01449 0.3582982 
CDK1 0.00653 0.3954157 
CDK2 0.02292 0.3348748 
CDK6 0.00018 -0.525439 
CDKN1A 0.04155 0.3017465 
CDKN2A 0.00001 0.600167 
CHGA 0.00012 -0.6890271 
EGFR 0.01393 -0.3602222 
ERCC1 0.00322 -0.4252979 
FLT4 0.01031 -0.3746669 
FOLR1 0.00010 -0.5412263 
FPGS 0.00205 -0.6358421 
GAB1 0.00182 -0.4475503 
MAN2C1 0.00231 -0.4383885 
MLH1 0.01863 -0.345652 
MMP3 0.02327 0.3340618 
MST1R 0.04339 0.2992018 
NTS 0.05859 0.2809346 
PAX5 0.02111 0.3391859 
PAX6 0.02668 0.3267251 
RTN1 0.00638 -0.3964781 
SEMA3B 0.02573 -0.3286917 
SOD1 0.04511 -0.2968973 
SOX11 0.00131 0.4598031 
SOX4 0.00019 0.5234697 
STK11 0.01985 -0.3423988 
SYP 0.00083 -0.4758176 
TKTL1 0.07582 0.2643776 
TYMS 0.00038 0.5022331 
UCHL1 0.05845 -0.2810818 
XRCC1 0.03428 -0.31282 
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Corresponding box plots regarding targets highlighted in Table 10 and Table 11 are 
shown in Figure 13 to 15. 
 
 
Figure 13 mRNA expression patterns of different genes measured by the NanoString 
technology. All illustrated genes decrease in their gene expression with increasing 
malignancy of the NET. FOLR1, CDK6 and SYP show very low median expression levels in 
NE carcinomas, especially when compared to pulmonary carcinoids. MLH1 is significantly 
higher in carcinoids then in high-grade tumours, but also carcinomas still have a noteable 
expression level. CHGA was the strongest expressed gene of all targets. Its y-axis is 
logarithmically scaled. 
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Figure 14 mRNA expression patterns of different genes measured by the NanoString 
technology are shown. All illustrated genes increase in their expression level with higher 
aggressiveness of the tumour. TYMS, CDKN2A and SOX4 show nearly no expression in 
carcinoid tumours but a detectable (LCNEC) to strong (SCLC) expression in high-grade 
carcinomas. PAX6, RBP1 and SOX11 are absent in carcinoids and LCNEC but expressed in 
SCLC. 
 
 
Figure 15 The boxplots present mRNA expression pattern of BCL2 investigated by 
NanoString nCounter technology and the BCL2/BAX-ratio as marker for evade of apoptosis, 
respectively. The BCL2 expression increases with increasing malignancy of the tumour 
entity. Whereas the BCL2/BAX ratio is nearly even in TC, the potential to evade apoptosis 
increases from AC over LCNEC to the highest value in SCLC. 
 
Moreover, possible correlations with TNM parameters (tumour size, lymph node 
infiltration and metastasis) and additional parameters including International 
Association for the Study on Lung Cancer (IASLC)-stage, blood and lymphatic vessel 
invasion were investigated. With regard to tumour size, CYP1A1 and SOX11 showed 
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significant correlations. FOLR1 was identified as most significant marker for lymph 
node invasion. CDKN2A, FPGS, MAN2C1, PAX5, PAX6, SOX11 were highly 
significant and eight genes were significant for N-status. For metastatic behaviour 
PAX6 was most significant, followed by SOX11 as highly significant marker. Eight 
additional genes exhibited significant correlations: For stage FOLR1 was highly 
significant and six significant genes were found. For blood vessel invasion 13 
significant genes were identified. Lymphatic vessel invasion showed highly significant 
correlations with CHGA and XRCC1 as and also exhibited four additional markers 
that reached significance. Correlations for gender and expression were also 
investigated. NKX21 was most significant and FLT4, FOLR1, SYP and UCHL1 were 
highly significant for gender. Additionally, 17 significant markers were identified 
correlating with gender. A summary of significant correlations with extended TNM-
staging criteria is given in Table 12. 
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Table 12 P-values of mRNA expression regarding several clinical variables (TNM) using the 
Spearman Test are shown. Highly significant mRNAs are bolded; most significant mRNAs 
are highlighted in grey. 
mRNA vs. stage  p-value rho 
CHGA 0.03605 -0.3099615 
EGFR 0.02803 -0.3240392 
ERCC1 0.01472 -0.3575023 
FOLR1 0.00493 -0.4076321 
MLH1 0.02144 -0.3383752 
SYP 0.03083 -0.3187732 
XRCC1 0.02255 -0.3357298 
mRNA vs. M-status    
CDK2 0.02908 0.3088549 
MSH6 0.03493 0.2989902 
PAX6 0.00023 0.4989672 
RBP1 0.01465 0.3433212 
SOX11 0.00125 0.4435477 
TYMS 0.02283 0.3214435 
mRNA vs. N-status   
BCL2 0.02244 0.3223341 
CAT 0.04844 -0.2805598 
CCND1 0.03505 -0.2988 
CDKN2A 0.00116 0.4464135 
CHGA 0.01808 -0.333135 
EGFR 0.01591 -0.3393525 
FOLR1 0.00011 -0.5192756 
FPGS 0.00379 -0.402118 
MAN2C1 0.00457 -0.3946589 
MLH1 0.01111 -0.3562231 
PAX5 0.00469 0.3935955 
PAX6 0.00521 0.3892678 
SEMA3B 0.02975 -0.3076474 
SOX11 0.00380 0.4020669 
SYP 0.02131 -0.3249457 
 
Concerning PFS, nine significant correlations were found. The Score (logrank) test 
showed the most significant correlation for OCT4 and significant correlations for 
FIGF, FN1, FOLR1, HIF1A, NTS and FAS. The likelihood-ratio test revealed 
GABBR2, OCT4 and PCDHB9 as significant markers.  
Kaplan Meier Curves of most important PFS results are shown in Figure 16. 
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Figure 16 Kaplan-Meier curves for significant results regarding expression-dependent PFS in 
the group of high-grade pulmonary NET. A high expression level of NTS and HIF1A is 
associated with shortened time to progression, respectively. Low level expression of FOLR1 
leads to an early recurrence of the tumour, whereas in contrast a loss of OCT4 expression is 
associated with prolonged PFS in this group of tumours. 
 
Overall survival (OS) correlated significantly with nine genes: the Score (logrank) test 
identified PAX6 as most significant (p<0.001), OCT4 as highly significant (p<0.01) 
and CRHR2, FPGS, MAN2B1, SOX11 and TP53 as significant (p<0.05) markers for 
OS. The likelihood-ratio test identified significant correlations for CHGA, FOLR1, 
FPGS, MAN2B1, SOX11 and a highly significant correlation for PAX6. Additionally, 
OCT4 was identified as significant marker.  
Kaplan Meier Curves of most important OS results are shown in Figure 17. 
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Figure 17 Kaplan-Meier curves for significant results regarding expression-dependent OS. A 
low PAX6 or OCT4 expression is associated with prolonged, a low FPGS or MAN2B1 
expression is associated with shortened overall survival in LCNEC and SCLC, respectively. 
 
Results of Variant Detection 
Run Parameters and Determination of Sequencing Quality 
Seventy of 74 patients were sequenced within four MiSeq runs, containing 23 or 24 
patient samples per run. Samples showing insufficient coverage of some loci (n=23) 
were re-sequenced with an additional fifth run. 
Bridge amplification of the target regions on the flow cell resulted in an average 
cluster density of 641 K/mm2 with approximately 80% of the generated clusters 
passing the quality filter parameters. Altogether, the sequencing runs produced an 
average of 3.65x106 reads and an average output of 1.1 gigabases. The runs 
showed read quality parameters with average Q30 scores (equals a 0.1% chance of 
a wrong base call at this position) about 63% in a range of 28%-85%. 
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Run parameters are summarised in table 13. 
 
Table 13 Overview of the technical run parameters for all five MiSeq runs. In run 5, the 23 
samples with the lowest median coverage or insufficient representation of some loci were 
resequenced.  
 Run 1 Run 2 Run 3 Run 4 Run 5 Average 
Samples 23 24 23 24 23  
Panel 
TSCP 
(Illumina) 
TSCP 
(Illumina) 
TSCP 
(Illumina) 
TSCP 
(Illumina) 
TSCP 
(Illumina) 
 
Amplicons [n] 181 181 181 181 181 181 
Cluster Density [K/mm²] 339 1,211 498 454 705 641 
Cluster PF 87.59% 56.88% 89.07% 89.64% 72.62% 79.16% 
Reads 2.83M 8.66M 4.04M 3.69M 5.43M 4.93M 
Reads PF 2.48M 4.93M 3.60M 3.31M 3.95M 3.65M 
Total Yield 0.8Gb 1.5Gb 1.1Gb 1.0Gb 1.2Gb 1.1Gb 
≥ Q30 Score 75.00% 42.90% 83.70% 85.30% 27.60% 62.9% 
TSCP… TruSeq Cancer Panel, PF… passed filter; Q30 Score… 0.1% chance of wrong base call;  
M… million; Gb… gigabases 
 
After the primary alignment, 25,940 genetic variants could be determined. 7,041 of 
them were classified as synonymous, leading to no change of the amino acid 
sequence. 643 of the remaining 18,899 variants detected fulfilled the criteria of more 
than 10% mutated allelic fraction and more than 25 mutated reads absolute. 
An algorithm for variants filtering is illustrated in Figure 18. 
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Figure 18 The chart pies summarises the algorithm used for variant filtering. Starting from 
25,940 variants detected with the preliminary variant calling, going on with removing of 
synonymous variants that led to 18,899 variants. After a final filtering of variants below 10% 
of total reads or less than 25 mutated reads absolute 634 variants were determined.  
 
Approximately 60% of the targets showed coverage between 500 and 2,000 reads 
(Figure 19). 
 
 
Figure 19 The histogram demonstrates the distribution of the reads past filter (PF) from all 
targets and runs. The y-axis shows the number of clusters that passed the initial filter 
process, the x-axis shows the coverage of these loci merged from each sample. Most targets 
had a median coverage between 500 and 2,000bp. 
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Variant Calling and Distribution of Detected Mutations 
Regarding 643 variants that passed the applied filter processing as described above, 
122 variants were related to TC (mean: 7.2 mutation in each sample), 150 were 
found in AC (mean: 8.8 variants per sample) and 164 were related to LCNEC (mean: 
9.6 variants per sample). The final 207 variants were detected in the SCLC samples 
(mean: 14 variants per sample).  
Most frequent alterations were found in FLT3 (70) followed by APC (69) and TP53 
(59).  
 
An overview of the mutation frequency per gene as well as the percentage of 
samples of each entity showing variants at this locus is summarised in Table 14. 
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Table 14 The table shows the results of the variant calling. The mutation frequency per gene 
as well as the percentage of samples of each entity showing at least one mutation at this 
locus is illustrated. 
 Gene Variants (abs.) Ø TC Ø AC Ø LCNEC Ø SCLC 
ABL1 7 11.76% - 15.79% 6.67% 
AKT1 2 - 5.88% - 6.67% 
ALK 2 - 5.88% 5.26% - 
APC 69 35.29% 35.29% 26.32% 40.00% 
ATM 22 29.41% 17.65% 15.79% 40.00% 
BRAF 3 - - 10.53% 6.67% 
CDH1 1 - 5.88% - - 
CDKN2A 0 - - - - 
CSF1R 0 - - - - 
CTNNB1 1 5.88% - - 6.67% 
EGFR 16 23.53% 23.53% 21.05% 26.67% 
ERBB2 35 29.41% 29.41% 31.58% 33.33% 
ERBB4 15 17.65% 11.76% 10.53% 20.00% 
FBXW7 13 5.88% 29.41% 31.58% 6.67% 
FGFR1 2 - 5.88% 5.26% - 
FGFR2 7 17.65% 5.88% 10.53% - 
FGFR3 4 11.76% 5.88% 5.26% - 
FLT3 70 100.00% 88.24% 89.47% 100.00% 
GNA11 0 - - - - 
GNAQ 0 - - - - 
GNAS 2 5.88% 5.88% - - 
HNF1A 4 - 5.88% 10.53% 6.67% 
HRAS 0 - - - - 
IDH 6 17.65% - - 13.33% 
JAK2 0 - - - - 
JAK3 5 5.88% 5.88% 10.53% 6.67% 
KDR 41 47.06% 41.18% 57.89% 66.67% 
KIT 22 35.29% 35.29% 26.32% 20.00% 
KRAS 12 5.88% 29.41% 10.53% 20.00% 
MET 8 11.76% 11.76% 15.79% 6.67% 
MLH1 1 5.88% - - 6.67% 
MPL 0 - - - - 
NOTCH1 0 - - - - 
NPM1 0 - - - - 
NRAS 3 - - - 13.33% 
PDGFRA 12 23.53% - 15.79% 26.67% 
PIK3CA 28 17.65% 23.53% 26.32% 40.00% 
PTEN 34 23.53% 35.29% 21.05% 26.67% 
PTPN11 33 23.53% 35.29% 21.05% 26.67% 
RB1 13 11.76% 5.88% 21.05% 20.00% 
RET 11 11.76% 23.53% 10.53% 13.33% 
SMAD4 33 29.41% 29.41% 26.32% 26.67% 
SMARCB1 4 - 5.88% - 20.00% 
SMO 33 17.65% 23.53% 21.05% 13.33% 
SRC 0 - - - - 
STK11 8 - 11.76% - 20.00% 
TP53 59 29.41% 41.18% 73.68% 93.33% 
VHL 2 - - - 6.67% 
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Statistical Analysis 
Thirteen statistically significant associations between the mutation frequency per 
gene and tested variables could be ruled out. Additionally, nine correlations between 
mutational status of the genes and tested variables were found. 
Most conspicuous, all four entities of pulmonary neuroendocrine tumours differ 
significantly in their genetic profile of TP53 (p=0.0011, figure 20). Therefore, it seems 
to be of additional importance when TP53 shows multiple mutations (p=0.0001). 
 
 
Figure 20 Samples showing at least one TP53 variant regarding the tumour entity. The 
number of mutated samples increased from TC (below 30%) to SCLC (more than 90%). A 
sharp edge can be seen between carcinoid tumours (30%-40%) and high-grade carcinomas 
(75-95%). 
 
TP53 variants significantly correlated with the potential of the tumour to invade lymph 
nodes (p=0.0061). 
In addition, the number of mutations in APC (p=0.0433), BRAF (p=0.0468) and 
STK11 (p=0.0144) were associated with lymph-node invasion. Occurrence of any 
non-synonymous variant in APC (p=0.0262) and STK11 (p=0.0131) could predict a 
tendency for lymph vessel infiltration.  
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However, no correlations between the mutations detected and the occurrence of 
distant metastases, as well as to gender and size of the tumour detected could be 
observed. 
 
For progression-free survival analysis, the mutation frequency in APC, ATM, MET, 
KRAS, PDGFRA, PIK3CA and RB1 rendered significance in all three tests regarding 
PFS. The amount of mutations in FWXB7 correlated significantly with OS. 
Analogously, the occurrence of mutations in ATM, FLT3, MET, KRAS and RB1 
showed statistical significance to PFS and again FWXB7 was significant for OS. 
Important results are illustrated in Figure 21 and Figure 22. 
 
 
Figure 21 Kaplan-Meier curves of significant results regarding FBXW7. The occurrence of 
mutations within the coding sequence of FBXW7 is associated with shortened cumulative 
overall survival. 
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Figure 22 Kaplan-Meier curves of significant results regarding the mutation-dependent PFS 
analysis. Patients showing mutations in the CDS of either MET or KRAS have a highly 
significant shortened time to progression of the tumours. Also ATM and RB1 mutations 
significantly impact to progression of the tumours.  
 
Survival analysis is summarised in Table 15.  
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Table 15 Summary of significant results regarding the mutation-dependent survival analysis 
    
Gene 
Likelihood ratio 
Test 
Wald test 
Score (logrank) 
Test 
A
m
o
u
n
t 
o
f 
M
u
ta
ti
o
n
s 
OS FBXW7 0.0500 0.0352 0.0131 
PFS 
APC 0.0413 0.0347 0.0101 
ATM 0.0463 0.0379 0.0041 
MET 0.0027 0.9989 0.0001 
KRAS 0.0027 0.9989 0.0001 
PDGFRA 0.0592 0.0490 0.0186 
PIK3CA 0.0452 0.0367 0.0176 
RB1 0.0344 0.0303 0.0110 
M
u
ta
ti
o
n
 S
ta
tu
s
 
OS FBXW7 0.0500 0.0352 0.0131 
PFS 
ATM 0.0120 0.0221 0.0030 
FLT3 0.0216 0.9983 0.0003 
MET 0.0027 0.9989 0.0001 
KRAS 0.0027 0.9989 0.0001 
RB1 0.0424 0.0412 0.0191 
 
Proteasome Expression 
Overall Cohort 
Five genes of the 26S-proteasome complex coding for proteins of the catalytic 
domain and two additional reference genes as endogenous controls were tested for 
their mRNA expression levels using the TaqMan AoD. Efficacies calculated from the 
standard curves were between 1.89 and 2.01. The standard deviation was lower than 
0.4 Ct for any case and assay. None of the non-template controls (NTCs) generated 
a detectable signal. 2-ΔΔCt-values for the 26S-proteasome subunits were as follows: 
PSMA1 (3.5E-07 to 53.69; median: 1.35; mean: 2.70), PSMA5 (7.7E-06 to 901.20; 
median: 2.27; mean: 136.12), PSMB4 (1.3E-05 to 77.36; median: 1.61; mean: 3.54) 
and PSMD1 (9.9E-07 to 40.38; median: 1.32; mean: 3.78). GAPDH was between 
0.58 and 1.96 (median: 0.97; mean: 1.31) and ACTB was used for normalisation 
purposes. 
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The mRNA expression of the 26S-proteasome subunits demonstrated significant 
correlations to each other (p≤0.003; rho between 0.338 and 0.598), except PSMA5 to 
PSMB5 (p=0.69; rho=0.047); indicating that any of the 26S-proteasome subunits is 
equally expressed in these tumours and mRNA of each subunit was reliably 
detected. 
Compared to non-tumorous lung tissue, the gene expression of all 26S-proteasome 
subunits was significantly increased in any subtypes of pulmonary neuroendocrine 
tumours (PSMA1: p> 0.0001; PSMA5: p= 0.0002; PSMB4: p> 0.0001; PSMB5: p> 
0.0001; PSMD1: p> 0.0001) (Figure 23, Figure 24). PSMB4 gene expression was 
significantly different between the different neuroendocrine tumour subtypes 
(p=0.043, rho=0.262), showing the highest mRNA levels in LCNEC (Figure 25). All 
other 26S-proteasome subunit genes investigated did not show statistically significant 
differences between the different tumour entities. Furthermore, the proliferation index 
of pulmonary neuroendocrine tumours measured by nuclear expression of Ki-67 
showed a significant positive correlation to the mRNA level of PSMB4 (p=0.0039, 
rho= 0.301).  
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Figure 23 Box plots illustrating significantly upregulated mRNA expression in the different 
subtypes of pulmonary neuroendocrine tumours are shown. The gene expression measured 
by TaqMan qPCR is shown using log(2^-dCt) of each target. Horizontal bars indicate 
significant dependences. Note that any proteasomal subunit mRNA expression is 
significantly upregulated compared to controls obtained from non-tumorous lung tissue of 
patients with pneumothorax. Especially PSMB4 and PSMD1 show the strongest upregulation 
compared to benign lung. LCNEC show the broadest range of proteasomal expression 
pattern, maybe due to the heterogeneity of this entity. Remarkable is the relatively low 
PSMA5 expression level when compared to the control. 
 
 
Figure 24 The figure illustrates the results of the immunohistochemical staining of the 
proteasomal subunit PSMB4 in both, low-grade (A+B) and high-grade (C+D) pulmonary 
NET. Immunohistochemically, PSMB4 reactivity is strong in any subtypes of pulmonary NET. 
All NET are silhouetted against the encircling stroma. Immunohistochemical no differences 
between the four tumour entities could be detected. 
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Figure 25  Boxplot of PSMB4 expression levels between the different tumour types. In 
particular, the PSMB4 mRNA expression is upregulated in pulmonary NET compared to 
controls and differs significantly among the subtypes of pulmonary NET. PSMB4 shows the 
highest expression in LCNEC, the lowest expression in AC and SCLC. Nevertheless, 
immunohistochemically no differences between the four tumour entities could be detected, 
PSMB4 mRNA expression is higher in LCNEC/SCLC than in TC/AC. The gene expression 
measured by TaqMan qPCR is shown using log(2^-dCt) of each target. Horizontal bars 
indicate significant dependences.  
 
Pulmonary Neuroendocrine Carcinomas  
As observed in the overall cohort any measured mRNA expression levels of the 26S-
proteasome were significantly correlated to each other (p≤0.010) except 
PSMA5/PSMB5 (p=0.332; rho=0.159). 
PSMB4 gene expression level was significantly higher in LCNEC compared to SCLC 
(p=0.036) (Figure 26).  
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Figure 26 Differential expression of PSMB4 between the two types of high-grade NELC. 
LCNEC shows a slightly higher expression level then SCLC. The gene expression measured 
by TaqMan qPCR is shown using log(2^-dCt) of each target. Horizontal bars indicate 
significant dependences. 
 
Pulmonary Carcinoids Tumours 
PSMD1 is associated with Ki-67 expression (p=0.010; rho=-0.484) as well as 
chromogranin A- immunoexpression (p=0.015; rho=0.440). PSMB4 also showed a 
significant correlation to the proliferation index determined by Ki-67 
immunoexpression (p=0.046; rho=-0.387).  
PSMA1 (p=0.030, rho=-0.372) and PSMB5 (p=0.035, rho=-0.363) both show a 
significantly different gene expression between G1 or G2 carcinoid tumours of the 
lung (Figure 27). Additionally, PSMA5 (p=0.02389) and PSMB4 (p=0.050) showed 
higher expression in TC in comparison to AC.  
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Figure 27 Differential expression pattern of PSMA1 and PSMB5 in low-grade NELC. Among 
others, the gene expressions of PSMA1 (p= 0.030) and PSMB5 (p= 0.035) are significantly 
higher in TC compared to AC. The gene expression measured by TaqMan qPCR is shown 
using log(2^-dCt) of each target. Horizontal bars indicate significant dependences. 
 
Survival Analysis 
PSMD1 mRNA expression is significantly associated with OS of all subtypes of 
pulmonary neuroendocrine tumours (Likelihood ratio test: p=0.019; Score (logrank) 
test: p=0.020), but no correlation at all could be found for PFS (Likelihood ratio test: 
p=0.556; Score (logrank) test: p=0.558). 
 
Determination of Protein Expression by Immunohistochemistry 
Staining results of the immunohistochemical panel including Pan-Cytokeratin (CK-
MNF-116), NCAM (CD56), NKX2-1 (TTF-1), CHGA (chromogranin A), cleaved 
CASP3 (Casp3), PSMB4 and MKI67 (Ki-67), possible correlations to tumour type and 
survival times (OS/PFS) were calculated.  
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Three of them, namely CHGA (p=0.0004), Casp3 (p<0.0001) and Ki-67 (p<0.0001) 
differ significantly between these entities. CHGA is strongly expressed in carcinoid 
tumours but shows a weak to absent expression in the high-grade group. The 
proliferation index determined by Ki-67 expression increases as expected with 
increasing malignancy, showing nearly no proliferative activity in the low grade 
tumours, a moderate proliferation in LCNEC and a strong activity in SCLCs. 
Determination of initiated apoptosis via staining of already cleaved caspase3 shows a 
moderate to strong appearance in LCNEC and SCLC, a weak to moderate 
expression in TC and no apoptotic activity in AC. None of the IHC markers show a 
significant association to PFS or OS. 
Boxplots representing the results of the IHC staining are given in Figure 28. 
 
 
Figure 28 Boxplots illustrating results of the immunohistochemical staining of NELC against 
the neuroendocrine markers NCAM (CD56) and CHGA, CKMNF-116 and TTF1 as diagnostic 
standards, Ki67 for proliferation and CASP3 to determine the apoptotic activity fraction. 
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4. Discussion 
In contrast to neuroendocrine tumours of other organ systems (e.g., of 
gastrointestinal origin), pulmonary neuroendocrine tumours form two distinct, 
prognostically different groups: the low-grade (LG) carcinoid tumours and the high-
grade (HG) carcinomas (Rindi et al. 2014). Both groups can be further divided into 
subgroups, namely TCs and ACs and LCNECs and SCLCs, respectively.  
Both pulmonary carcinoids and SCLCs were previously reported to arise from PNEC 
(Bensch et al. 1968; Warburton et al. 2000; Swarts et al. 2012). Even though all four 
subgroups share some morphologic and molecular properties, it is still unclear 
whether they are different biological entities or a distinct tumour entity showing 
different grades of differentiation and hence different biological behaviours. The aim 
of this thesis was to address some aspects of this question. To this end, a broad 
molecular-biological screening was performed to explore numerous cellular 
processes on different levels including genetic background, individual expression 
pattern, transcriptional regulation via miRNAs and cellular protein levels. 
 
Development of a New Model for Lung Tumour Classification 
Pulmonary neuroendocrine tumours should be clearly separated from other NSCLCs. 
These tumours originate from precursor lesions different to pulmonary 
neuroendocrine tumours and do not share many molecular characteristics with 
NSCLCs. Thus, the clinical management of LCNEC should move closer to that for 
SCLC than for NSCLC (Iyoda et al. 2014). 
A conclusive proof of our hypothesis can only be achieved through genetic or 
epigenetic analysis, because gene expression levels can strongly differ and also 
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depend on environmental influences. The use of formalin-fixed paraffin embedded 
tissue is standard and crucial in routine molecular diagnostics.  As has been known 
for more than forty years, formalin fixation of tissues can lead to DNA alterations like 
DNA fragmentation, deamination of cytosine to adenine and cross-linking between 
protein and DNA (Chalkley and Hunter 1975). It is well known that the formalin 
fixation process lowers the success of PCR (Chalkley and Hunter 1975), which could 
therefore lead to an impaired library construction for NGS. The amplification of FFPE 
DNA can result in the production and amplification of artificial mutations, which 
ultimately produces many sequencing artefacts. A visual verification of our 
sequencing data with the alignment-visualizer program integrative genomics viewer 
(IGV, Broad Institute of MIT and Harvard, Boston, USA) revealed a high background 
of unspecific variant calls (Figure 29). Due to the high number of sequencing 
artefacts, leading to a high number of false positive variants, the sequencing results 
obtained must be treated with caution. 
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Figure 29 The visual analysis of the next generation sequencing data by integrative 
genomics viewer shows a high background of false-positive variants for APC exon 14. Pink 
bars show sequenced forward strand, blue bars show sequenced reverse strands. Colour 
dots within the strands display discrepancies between the base calls and the hg19 reference 
build. 
 
Despite these shortcomings, the sequencing data give a clear impression of the 
genetic background of the different tumour subgroups. The major finding was the 
different proportion of loss-of-function (LOF) mutations in the TP53 gene locus, 
ranging from less than 30% in TCs up to more than 90% in SCLCs. This is in line with 
previous findings from other studies (Lohmann et al. 1993; Przygodzki et al. 1996; 
Couce et al. 1999; Leotlela et al. 2003; Swarts et al. 2012). LOF of the p53 protein, 
considered the “guardian of the genome,” is fundamental to most of the differences 
between the high-grade and low-grade NELC groups, including the increased genetic 
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instability of high-grade tumours or the evasion of apoptosis. The epigenetic 
screening for DNA-methylations is addressed in an ongoing study.  
These substantial differences between pulmonary carcinoids and high-grade lung 
NETs with regard to gene and protein expression levels and mutations of important 
tumour suppressor genes (especially TP53) and oncogenes may simply reflect 
differences in the exposure to tobacco carcinogens, probably causing further genetic 
alterations. An improved understanding of the biology of NETs will offer the 
opportunity for novel approaches in clinical management, resulting in better 
prognosis and prediction of therapeutic response (Asamura et al. 2006). At present, 
LCNECs are assigned to the NSCLC group and patients receive clinical management 
in accordance with NSCLC guidelines. Interestingly, patients with LCNEC receiving 
an SCLC-based regimen showed a significantly improved overall survival compared 
to those receiving standard regimes for NSCLC (Rossi et al. 2005; Gridelli et al. 
2013). 
Figure 30 illustrates our proposal for a classification model of lung tumours. 
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Figure 30 Proposal for a model for classifying lung tumours. Despite the traditional 
morphologic view and classification into NSCLC and SCLC, which has been undisputed for 
generations of medical doctors, the family of pulmonary neuroendocrine tumours, although 
showing different morphological presentation, can be biologically distinguished from all other 
forms of lung cancers. 
 
miRNA Expression in NET of the Lung and NSCLC 
In the past, a small set of miRNAs were identified as distinguishing between different 
types of lung tumours, playing a driving role in tumourigenesis of lung cancers and/or 
having a prognostic or predictive impact on these tumours. Unfortunately, the 
overwhelming majority of these studies focused on NSCLC patients; no joint data for 
pulmonary neuroendocrine tumours currently exist.  
 
Expression of miR-29 family members correlates with increasing malignancy of the 
investigated tumour entities. Their expression decreases with increasing 
aggressiveness of the tumour. It is known for LCNEC that the expression of miR-29 
family members is strongly associated with the methylation pattern of the cells by 
targeting the DNA-methyltransferases 3A and 3B (DNMT3A/DNMT3B). Its function is 
required for de novo methylation and for establishment of DNA methylation patterns 
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during development. Therefore a high methylation pattern is present, but inducing 
expression of miR-29 restores normal pattern and re-expression of silenced tumour 
suppressor genes like FHIT in cell lines (Fabbri et al. 2007). This leads to a 
reprogramming of the tumour cells to the methylation pattern of a non-tumorous cell, 
indicating that the miR-29 family (especially miR-29a, miR-29b, miR-29c) are acting 
as tumour suppressor-miRNAs (Fabbri et al. 2007). Hence, a down-regulation of 
miR-29 expression is accountable for hypermethylation and frequently induces 
silencing of tumour suppressor genes. Other targets of the miR-29 family include 
p85α and CDC42 (Park et al. 2009). CDC42 and p85α are negative regulators of 
p53, which displays apoptotic activity. Lower expression reduces p53 levels, 
associated with decreased apoptosis, which correlates with increasing malignancy. 
Although the expression within TC and AC is similar, Figure 10 shows a clear 
difference between low and high grade lung tumours and between LCLC and SCLC.  
 
miR-34 family members are thought to be associated with the p53 tumour suppressor 
network, inhibiting inappropriate cell proliferation (He et al. 2007). Nevertheless, the 
difference between the four tumour types analysed in this study has not shown a 
correlation to any of them. As reported by Lee et al. (Lee et al. 2011), none of the 
miR-34 family members can be used as a prognostic marker in neuroendocrine lung 
cancers, including SCLC.  
 
Members of miRNA family let-7 have been found to be deregulated in human lung 
cancers, including cancers with neuroendocrine differentiation (Caldas and Brenton 
2005; Lee et al. 2012). In contrast to the published data, these miRNAs were unable 
to discriminate the different entities of neuroendocrine lung cancers in our collective, 
but let-7d showed a significant correlation with overall survival in these patients, 
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leading to the assumption that let-7d plays a role in the development of metastasis 
and progression of these tumours. The miRNAs miR-21 and miR-155, both reported 
to be overexpressed in neuroendocrine lung cancers (Guan et al. 2012; Lee et al. 
2012), showed no statistical significance in our collective, just like miR-210, an 
miRNA overexpressed in cancer tissue and not in normal lung parenchyma (Guan et 
al. 2012). miR-21 turned out to be a particularly interesting target, because it is a key 
regulator of the MTOR pathway and is reported to be differently regulated in 
neuroendocrine tumours (Cingarlini et al. 2012). This also matches the results of our 
mRNA analysis, as described below. Additionally, miR-96 expression coincides with 
the methylation pattern of cells and has been shown to be upregulated in NSCLC 
(Ma et al. 2011), but there is no suggestion that it could be a potential diagnostic 
marker between the tumour types investigated in this study.  
 
One interesting result in this context is the differential expression of the miR-143 
between the different tumour types. miR-143 mainly targets the hexokinase 2 gene, 
the key regulator of glycolysis, which is activated in a majority of human cancers 
(Fang et al. 2012). The expression of miR-143 decreases with higher malignant 
potential of the tumour, leading to increased glycolytic activity (known as the Warburg 
effect). This result leads to the assumption that the higher proliferative activity of 
high-grade neuroendocrine cancers requires a higher metabolic activity and depends 
on the glycolytic utilization of glucose. The dysregulation of members of the glycolytic 
system, such as MAN2B1, also supports this finding. 
 
MAPK Pathway  
One of the most promising results yielding the most hits within the pathway analysis 
is the mitogen-activated protein kinase (MAPK) pathway. Recently, West et al. have 
 
 
87 
shown that nicotine stimulates tumour growth in NSCLC through AKT- and MAPK-
dependent mechanisms, and that modulation of AKT signalling pathways may 
provide a target for directed therapy (West et al. 2003; Castillo et al. 2004; Song et al. 
2007). 
The MAPK pathway is one of the most important intracellular signalling cascades 
conserved from yeast to mammals (Widmann et al. 1999; Vicent et al. 2004). MAPKs 
are intracellular serine/threonine kinases that regulate cell survival and proliferation 
and may play a role in KIT signal transduction (Blackhall et al. 2003). Their three 
main components are the extracellular signal-regulated kinase (ERK), c-jun NH2-
terminal kinase (JNK) and p38 (Cano and Mahadevan 1995; Su and Karin 1996; 
Vicent et al. 2004). Activation of any of the MAPK family members requires 
phosphorylation of two regulatory residues (a threonine and a tyrosine) by their 
upstream kinases (Widmann et al. 1999; Vicent et al. 2004). Dephosphorylation of 
one or both of these regulatory residues induces deactivation of MAPK family 
members (Vicent et al. 2004). 
KIT, AKT (also known as PKB) and MAPK are expressed in a high percentage of 
SCLCs, suggesting that MAPK is an independent tumour driver in this malignancy 
(Blackhall et al. 2003). Activation of this pathway caused a dramatic loss of soft agar 
cloning ability, suppression of growth capacity, associated with cell accumulation in 
G1 and G2, and S phase depletion in cell line experiments (Ravi et al. 1998; Ravi et 
al. 1999).  
Additionally, within the G protein-coupled receptors signalling to MAPK/ERK 
pathway, we found the currently routinely analysed KRAS mutations (p.G12D and 
p.Q61L, respectively) in more than 10% of LCNECs and about 5% of ACs and 
SCLCs, with about 30% mutated alleles and a good read quality. Interestingly, these 
findings are contrary to the results published in a recent paper addressing this 
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question (Przygodzki et al. 1996). Activating KRAS mutations are strongly associated 
with exposure to tobacco smoke; therefore, an accumulation of KRAS mutations in 
these tumours seems expedient.  
 
PI3K Pathway 
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of the rapamycin 
(mTOR) signaling pathway shows significant differences between the four types of 
pulmonary neuroendocrine tumours investigated in this study. 
Abberant activation of the PI3K/Akt/mTOR signaling pathway (Burnett et al. 1998) 
has been widely investigated in the pathogenesis of many cancers (Yamamoto et al. 
2008; Liu et al. 2009; Courtney et al. 2010; Wong et al. 2010; Papadimitrakopoulou 
2012; Spoerke et al. 2012) and has also been known to be activated during the early 
phase of lung cancer onset (West et al. 2004; Jeong et al. 2012), thereby causing 
cell growth, proliferation, angiogenesis and synthesis of various proteins (Janku et al. 
2010; Jeong et al. 2012; Reungwetwattana et al. 2012). Constitutive activation of this 
pathway also leads to upregulated proliferation, evasion of apoptosis and altered 
metabolism via the Warburg effect (Spoerke et al. 2012). In addition, increased 
pathway activity has been associated with resistance to anti-cancer therapies (Myers 
and Cantley 2010; Spoerke et al. 2012). When PI3K and Akt are activated by the 
stimulation of various growth factors by transmembrane receptor tyrosine kinases 
(RTKs), including EGFR, HER2, IGFR, VEGFR and PDGFR (Li et al. 2009), they 
activate mTOR (Jeong et al. 2012). The activated mTOR in turn regulates eukaryotic 
initiation factor 4E binding protein-1 and 40S ribosomal protein S6 kinase (p70S6K), 
which are involved in the regulation of protein synthesis (Janku et al. 2010; Jeong et 
al. 2012; Reungwetwattana et al. 2012).  
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PI3K-dependent activity is frequently high because of amplification (Shayesteh et al. 
1999) or gain of function mutations of the PIK3CA gene (Samuels et al. 2004) as well 
as loss of function of the PTEN tumour supressor gene, a critical negative regulator 
of this pathway (Sansal and Sellers 2004; Spoerke et al. 2012). It has been reported 
that PIK3CA gene mutation and its amplification are observed in approximately 2% 
and 12-17% of patients with NSCLC, respectively (Kawano et al. 2006; Kawano et al. 
2007; Yamamoto et al. 2008; Jeong et al. 2012). In addition, increased pathway 
activity has been associated with resistance to anti-cancer therapies (Clark et al. 
2002; Wallin et al. 2010; Spoerke et al. 2012). 
Furthermore, resistance to apoptosis is an important hallmark of tumour cells 
(Hanahan and Weinberg 2011; Zhu et al. 2012). Apoptosis of tumour cells is known 
to be regulated by a variety of signalling pathways, including the PI3K/Akt pathway 
(Zhu et al. 2012). AKT has been shown to regulate apoptosis related proteins such 
as Bcl-2, Bax and caspase-3 (CASP3) and is crucially involved in anticancer drug 
induced apoptosis of cancer cells (Takeuchi et al. 2005; Lee et al. 2006; Li et al. 
2009; Bak et al. 2011; Zhu et al. 2012).  
The significance of PI3K signalling for tumour survival and proliferation has led to the 
development of candidate therapeutics designed to inhibit the activity of pathway 
components such as PI3K, mTOR and Akt (Spoerke et al. 2012).  
 
TGF-β Pathway 
Several malignancies have been screened for the presence of transforming growth 
factor beta (TGFB1) and its receptor (TGFBR1), but in human lung cancer the data 
are very sparse (Damstrup et al. 1993). A few studies have demonstrated that 
TGFB1 mRNA was expressed only in NSCLC cell lines (Derynck et al. 1985; Bergh 
1988; Soderdahl et al. 1988; Damstrup et al. 1993); in another study all of the ten 
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SCLC cell lines examined were found to be TGFB1 mRNA negative (Lagadec et al. 
1991; Damstrup et al. 1993). The present data suggest a connection between 
tumourigenesis and TGF-β signalling in neuroendocrine lung tumours. 
TGF-β comprises a family of polypeptides which have been shown to be 
multifunctional regulators of basic cellular functions such as proliferation, 
differentiation, cell adhesion and interactions with the extracellular matrix (Massague 
1990; Moses 1992; Norgaard et al. 1994). Also angiogenesis and response to 
hypoxia are regulated by TGF-β dependent signalling mechanisms. 
Some carcinomas are resistant to the growth inhibitory effect of TGF-β, which in 
several cases has been ascribed to a lack of type 2 receptor (RII) (Geiser et al. 1992; 
Inagaki et al. 1993; Norgaard et al. 1994; Park et al. 1994; Hougaard et al. 1999). 
Recently, it was shown that TGF-β acts as a growth inhibitor of carcinomas in vivo, at 
least during early tumour growth (Cui et al. 1994; Pierce et al. 1995; Hougaard et al. 
1999). 
 
Cell Cycle and Proliferation 
Genes regulating the cell cycle and proliferation are deregulated in most human 
malignant tumours, and also in pulmonary neuroendocrine tumours (Russo et al. 
1998; Coe et al. 2006; Husain et al. 2012). mRNA expression of ten genes involved 
in the regulation of cell cycle and proliferation were investigated: CDKN2A (p16/INK4) 
is a cyclin-dependent kinase inhibitor preventing the phosphorylation of 
retinoblastoma protein 1 (RB1), thus functioning as a major cell cycle inhibitor at the 
G1 checkpoint (Husain et al. 2012). In this study, CDKN2A gene expression showed 
significant correlations with tumour type, grade and lymph node invasiveness. Coe et 
al. reported segmental loss and decreased expression of CDKN2A in NSCLC 
compared to SCLC (Coe et al. 2006). This is consistent with our findings, as we 
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detected the highest CDKN2A expressions in SCLC. CDKN2A also interacts with 
cyclin-dependent kinase 6 (CDK6) by forming a complex (Wang et al. 2013). CKD6 
drives cell cycle progression and inactivates RB1 by phosphorylation (Russo et al. 
1998). Additionally, CDK6 associates with CCND1 (cyclin D1), another positive 
regulator of cell cycle progression and RB1 phosphorylation (Brambilla et al. 1996). 
Both CDK6 and CCND1 have been reported to be involved in tumourigenesis 
(Brambilla et al. 1996; Russo et al. 1998; Wang et al. 2013). Our data demonstrate 
that CDK6 is expressed significantly more in both TCs and ACs than LCNECs and 
SCLCs, and CCND1 expression was inversely correlated with the pathological 
grading of the tumour. 
 
Apoptosis, BCL2-BAX Ratio, P53 and its Regulation 
Genetic alterations and inactivation of the tumour suppressor gene TP53 are known 
in most human malignant neoplasias (Brambilla et al. 1996). In our study, TP53 
overexpression was significantly associated with decreased OS. Additionally, we 
evaluated sequencing data of mutation hotspots in the TP53 gene locus and found 
LOF mutations in approximately 90% of SCLC samples, decreasing for LCNEC (ca. 
75%), AC (ca. 40%) and TC (ca. 30%). Sequencing data indicates that TP53 has lost 
its function, but a negative feedback loop seems to lead to overexpression in these 
patients in order to compensate for that loss. Therefore, TP53 expression increases 
with increasing malignancy of the tumour that correlates with a higher number of 
TP53 mutated tumours.  
FAS is a mediator of extrinsic apoptosis and recruits several other proteins for that 
purpose (Oh et al. 2012; Aguirre et al. 2013). After associating with other proteins, it 
also activates initiator-caspases like CASP8 and downstream caspases (D'Agati and 
Perzin 1985; Damstrup et al. 1993). In contrast, FAS was reported to also be 
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involved in cell survival and stress response (Oh et al. 2012). Deregulation of 
proteins involved in apoptosis was reported to contribute to tumour development and 
maintenance (Oh et al. 2012; Aguirre et al. 2013). We identified overexpression of 
FAS to be a negative marker for PFS. Furthermore, cleaved caspase-3 
immunoexpression correlates with increasing malignancy, indicating a higher 
potential for apoptotic activity in high-grade NETs. It must be remembered that high-
grade tumours use multiple ways to evade apoptosis; therefore, the increased 
availability of activated CASP3 did not show an association with increased apoptosis 
in this subgroup. CASP8 expression was significantly lower in carcinoids than in 
carcinomas. Kikuchi et al. reported that a knockdown of CASP8 reduced tumour 
growth and increased cell death (Kikuchi et al. 2012). They suggested that the 
protease activity of CASP8 is essential for tumour maintenance (Kikuchi et al. 2012). 
Additionally, death-inducing signalling complex (DISC) containing FAS and CASP8 
was identified as an essential component of embryonic development in mice (Kikuchi 
et al. 2012). This might indicate that high-grade tumours with elevated proliferation 
depend on the protease activity of the DISC.  
Furthermore, apoptosis is regulated by BCL2 and BAX. BAX is a mediator of 
apoptosis, whereas BCL2 acts inversely (Brambilla et al. 1996; Kobayashi et al. 
2004). The BCL2/BAX ratio is an adequate tool to assess the likelihood that a given 
cell will undergo apoptosis (Brambilla et al. 1996; Kobayashi et al. 2004). Higher 
BCL2 expression was reported in LCNEC and SCLC in contrast to AC and TC, where 
higher BAX expression was found (Brambilla et al. 1996; Kobayashi et al. 2004). Also 
in our study, the BCL2/BAX ratio increased with tumour type. Carcinoids showed a 
ratio of nearly 1, whereas carcinomas showed a ratio of ≥1. A ratio close to 1 
indicates that apoptosis and proliferation are balanced, whereas elevated ratios 
indicate a skew towards proliferation. Additionally, BCL2 was reported as a 
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prognostic marker in several solid and hematopoietic malignancies (Srivastava and 
Grizzle 2010). In our study, BCL2 and BAX exhibited no significant correlation with 
prognosis, but BCL2 was inversely correlated with the grade of differentiation.  
 
Angiogenesis 
Angiogenesis and lymphangiogenesis are important characteristics of aggressive 
tumours, resulting in the formation of metastases (Harris et al. 2011; Yu et al. 2013). 
Yu et al. reported that increased expression of VEGFA and KDR (VEGFR(-2)) 
correlated with progression of the tumour (Yu et al. 2013). In our study, an absence 
of KDR expression was significantly associated with blood vessel invasion, and its 
expression was only found in tumours without an infiltration of blood vessels. An 
association of FIGF (VEGFD) and HIF1A overexpression with disease progression 
was noted. Yu et al. also identified HIF1A, a transcription factor that regulates genes 
that respond to hypoxia, as being overexpressed in lung cancer. They proposed that 
this might be due to the hypoxic environment of a tumour and that this might trigger 
angiogenesis (Yu et al. 2013). In our study, HIF1A was identified as a significant 
marker for blood vessel invasion. The highest HIF1A expression was found in N0-
tumours. FIGF is an activator of KDR and FLT4 (VEGFR-3) and induces 
angiogenesis and lymphangiogenesis (Harris et al. 2011). In our study, FIGF and 
FLT4 correlated significantly with tumour type, and higher expression was more 
frequent in carcinoids than in carcinomas. Expression constantly decreased with 
poorer differentiation.  
 
Neuroendocrine Markers 
Routine immunohistochemistry analysis of neuroendocrine tumours relies on the 
detection of specific molecules, e.g., NCAM1 (CD56), SYP and chromogranin A 
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(CHGA) (Kashiwagi et al. 2012). CHGA and SYP correlated most significantly with 
grade of differentiation and tumour type. Both showed higher expression in 
carcinoids than in carcinomas, which is in line with our findings of a stronger 
immunoexpression of CHGA in TC/AC compared to neuroendocrine carcinomas. 
Similar results were also reported by Jensen et al. (Jensen et al. 1990). SYP showed 
a significantly higher expression in women than men. Additionally, low grade tumours 
showed increased expression of SYP and CHGA. High CHGA expression correlated 
with improved survival and with low lymphatic metastasis potential.  
Significant correlations regarding tumour type and grade were also observed for 
RTN1. RTN1 is involved in neuronal and neuroendocrine differentiation in tumours 
and normal tissue (Di Sano et al. 2007). It was reported that RTN1 may act as a pro-
apoptotic protein, but the function of this process is poorly understood (Pinton et al. 
2001; Di Sano et al. 2003). Our results indicate that RTN1 expression decreases with 
lower grade of differentiation, and a higher expression was observed in carcinoids 
compared to carcinomas. Fenretinide is a chemotherapeutical agent that induces 
apoptosis in tumours with RTN1 overexpression (Di Sano et al. 2007). It might enter 
further clinical development and may be proposed as a future drug for carcinoids with 
elevated RTN1 expression. 
Elevated expression of the neurotensin receptor 1 (NTSR1) and NTS were correlated 
with poorer survival rates and progression of the disease in stage I lung 
adenocarcinomas (Alifano et al. 2010). In our study, high NTS expression was 
associated with shortened PFS.  
Low GABBR2 expression correlated with poor response to treatment and worse PFS. 
Several studies addressed the function of this receptor for GABA and its role in 
synaptic transmission in the nervous system (Balasubramanian et al. 2007; Hannan 
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et al. 2011), but few studies investigated the role of GABBR2 in cancerogenesis 
(Stein et al. 2010).  
SEMA3B is a potential tumour suppressor in lung and breast cancer, involved in 
apoptosis induction (Castro-Rivera et al. 2008). It is frequently silenced (allelic loss 
and/or epigenetic silencing) in NSCLC, ovarian and breast cancer (Castro-Rivera et 
al. 2008). In our study, SEMA3B expression was detected in all pulmonary 
neuroendocrine tumours. Notably, a higher expression was found in carcinoids than 
in carcinomas.  
NCAM1 showed similar results to SEMA3B for expression and tumour type; these 
relations were found on both an mRNA and protein level. NCAM1 was reported to be 
expressed in all neuroendocrine tumours and is used as a routine marker for IHC 
(Kashiwagi et al. 2012). Additionally, Iqbal et al. suggested that elevated SOX4 
expression might induce NCAM1 expression in human myeloma (Iqbal et al. 2010). 
In our study, NCAM1 and SOX4 mRNA expression showed an inverted correlation 
with each other. 
 
Transcription Factors and Transcriptional Regulation  
OCT4 (POU5F1) is a transcription factor that is necessary to maintain and initiate the 
pluripotent state of stem cells. OCT4 and SOX2 (as well as KLF4 and MYC) are also 
essential for reprogramming fibroblasts to obtain induced pluripotent stem cells 
(Yamanaka and Blau 2010). OCT4 was identified as a tumorigenic factor in several 
cancer types, but its function in tumourigenesis is not fully understood (Ikushima et 
al. 2011). We found associations between OCT4 expression and both OS and PFS. 
High OCT4 expression correlated with reduced progression-free survival time and 
lower survival rates. These results fit well with a study proving that a knockdown in 
OCT4 increased sensitivity to chemotherapy (Ikushima et al. 2011).  
 
 
96 
SOX4 expression correlates with NCAM1 (CD56) expression and is a proto-
oncogene in a variety of tumours, including lung cancer (Castillo et al. 2012; Vervoort 
et al. 2012). It was linked to tumour development and progression by inhibiting 
apoptosis, promoting cell survival and facilitating the development of metastases 
(Castillo et al. 2012; Vervoort et al. 2012). In our study, SOX4 was most significant 
for grade of differentiation and tumour type, which were in line with reported results.  
SOX11 shares structural and functional characteristics with SOX4 and was also 
reported to be overexpressed in tumours (Dy et al. 2008). We noted significant 
associations between SOX11 expression and decreased OS. However, detectable 
expression was only found in SCLC. 
PAX6 is a transcription factor which plays a crucial role during organ development, 
being involved in crucial biological processes such as proliferation, apoptosis and 
differentiation, as well as in tumourigenesis (Mascarenhas et al. 2009; Zong et al. 
2011). In bladder cancer and prostate cancer, PAX6 was reported as a potential 
tumour suppressor (Hellwinkel et al. 2008; Shyr et al. 2010). It is supposed that PAX6 
plays an ambiguous role depending on the cancer type and development status of 
the tumour (Hellwinkel et al. 2008; Mascarenhas et al. 2009; Shyr et al. 2010; Zong 
et al. 2011). In our study, increased PAX6 expression correlated with tumour type, 
grade of differentiation, increased metastatic potential of the tumour, infiltration of 
lymph nodes and decreased OS.  
PAX5 is a transcription factor involved in the development of B cells, organs, 
differentiation of tissue and tumourigenesis (Song et al. 2010; Li et al. 2012). In our 
study, elevated expression of PAX5 correlated significantly with poorly differentiated 
tumours and lymphatic metastasis. Furthermore, PAX5 and PAX6 regulate the 
expression of MET (Mascarenhas et al. 2009; Song et al. 2010). Importantly, two 
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markers (PAX6, SOX11) were found to distinguish SCLCs from other neuroendocrine 
tumours. 
 
Additional Growth Factor Receptors 
In addition to VEGFRs and KDR (discussed above), EGFR is also a receptor tyrosine 
kinase involved in proliferation and cell survival (Takeda et al. 2013). For EGFR-
inhibition, several tyrosine kinase inhibitors (TKIs) exist (Johnson et al. 2013; Takeda 
et al. 2013). In our study, mRNA expression analysis of EGFR showed higher 
expression in carcinoids than in carcinomas. Reduced expression was observed in 
more aggressive tumours based on grade of differentiation, stage, invasion into 
lymph nodes and blood vessels. Elevated expression was also more common in 
female than male patients. FGFR1 is a tyrosine kinase that contributes to cell 
development. Alterations in this gene were reported in several cancer types (Weiss et 
al. 2010; Dutt et al. 2011). In addition, potential TKIs exist for FGFR1 (Weiss et al. 
2010; Dutt et al. 2011). In our study, FGFR1 was expressed significantly more in 
carcinoids than carcinomas.  
ALK is another receptor tyrosine kinase mediating neuronal development and 
differentiation (Dirks et al. 2002). Chromosomal translocations of the ALK gene into 
the loci of housekeeping genes can lead to constant expression due to the reference 
gene promoter and reportedly contributes to tumourigenesis (Dirks et al. 2002; 
Camidge et al. 2012). In our study, significantly elevated ALK mRNA expression was 
found in low-grade tumours, whereas high-grade tumours lacked ALK expression. 
Potent inhibitors exist for ALK inhibition (Camidge et al. 2012), which in this context 
could be considered for the treatment of chemoresistent low-grade neuroendocrine 
tumours. 
 
 
 
98 
Growth Factor Signalling via AKT/MTOR  
MTOR is a kinase involved in crucial cellular processes like cell growth, proliferation 
and differentiation by regulating downstream kinases like AKT and S6K (Zoncu et al. 
2011; Agrawal et al. 2012). RICTOR and RPTOR form complexes with MTOR, 
known as MTORC2 and MTORC1, respectively. MTORC1 is involved in translation, 
transcription, stress response and other important cell functions (Zoncu et al. 2011). 
MTORC2 is an important protein for actin regulation (Jacinto et al. 2004). MTORC1/2 
are involved in cancer development and maintenance (Zoncu et al. 2011). In our 
study, expression of RICTOR and RPTOR was reduced in LCNEC compared to the 
other entities. Additionally, RICTOR exhibited elevated expression in TCs. In 
conclusion, the investigation of the accessory proteins of each MTOR-complex can 
reveal more useful information than the investigation of MTOR alone for lung tumours 
with neuroendocrine features. Additionally, MTORC1 is sensitive to rapamycin 
treatment, whereas MTORC2 showed insensitivity to this inhibition (Jacinto et al. 
2004; Zoncu et al. 2011; Agrawal et al. 2012). 
Genes in the MET-pathway are overexpressed and active as oncogenes in several 
types of cancer (Mascarenhas et al. 2009; Zong et al. 2011). GAB1 is a mediator for 
cell survival, motility and morphogenesis and acts as an anti-apoptotic regulator 
when it has caspase-cleaved GAB1 status (Le Goff et al. 2012). In our study, GAB1 
showed higher expression in low-grade than in high-grade tumours.  
MET itself showed no differential expression in the investigated tumour types, which 
is in accordance with another study (Song et al. 2010). 
 
Folate Metabolism 
The folate metabolism is mandatory for normal cell proliferation and replication. 
Some antifolates such as fluoropyrimidines or pemetrexed inhibit thymidylate 
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synthetase (TYMS), ultimately resulting in cell cycle arrest (Ceppi et al. 2012; Wilson 
et al. 2012). In our study, TYMS expression was correlated with poorer differentiation.  
FPGS adds glutamate residues to folates and antifolates, thereby retaining them 
inside the cell (Odin et al. 2003; Mairinger et al. 2013). Loss of FPGS activity was 
reported to contribute to chemotherapy resistance in a variety of human malignancies 
(Liani et al. 2003; Stark et al. 2009; Christoph et al. 2012; Mairinger et al. 2013; 
Mairinger et al. 2013). In our study, FPGS expression was higher in carcinoids than 
in carcinomas and lymph node metastasis correlated inversely with its expression. 
Therefore, FPGS expression is a potential marker to distinguish metastasizing 
carcinoids from carcinoids that will not metastasize. Additionally, elevated FPGS 
expression is a marker for good prognosis.  
FOLR1 is a glycoprotein which transports folates through the cell membrane. This 
receptor is upregulated in several cancer types (Parker et al. 2005; Nunez et al. 
2012). Early and locally advanced adenocarcinomas, large cell carcinomas and 
carcinoid tumours express this receptor, but its expression in squamous cell 
carcinomas and SCLCs has rarely been observed (Franklin et al. 1994; Nunez et al. 
2012; O'Shannessy et al. 2012). In our study, expression in carcinoids was elevated 
compared to carcinomas and the expression in SCLC was at a minimum. 
Furthermore, decreasing FOLR1 expression correlated significantly with 
aggressiveness of the tumour in terms of lymph node metastasis. FOLR1 expression 
also exhibited prognostic and predictive value. Elevated expression was a marker for 
progression, whereas it was a good marker for prolonged survival. 
 
DNA Repair Mechanisms 
DNA mismatch repair is a crucial cell feature for maintaining accurate DNA 
replication during cell division (Kouso et al. 2008; Bischoff et al. 2012). Loss of 
 
 
100 
function of mismatch repair genes results in various aberrations like genomic 
instability, increased DNA mutations and microsatellite instability (Kouso et al. 2008; 
Bischoff et al. 2012).  
As we were able to show in malignant pleural mesothelioma, ERCC1 is an important 
member of this DNA repair machinery, removing cisplatin-induced DNA damages (de 
Jong et al. 2012; Ting et al. 2013). ERCC1 mRNA expression was higher in the 
carcinoid group than in high-grade carcinomas.  
MLH1 and MSH6 are further mismatch repair genes, which were found altered in 
several tumour types (de Jong et al. 2012; Ting et al. 2013). In our study, MLH1 
expression was elevated in carcinoids compared to carcinomas and MSH6 showed 
the highest expression in SCLC.  
XRCC1 is an important key protein in the base-excision repair pathway and mediates 
repair of single-strand breaks (Della-Maria et al. 2012; Erculj et al. 2012). XRCC1 
mRNA expression was significant for tumour type, grade of differentiation and 
lowered expression correlated with lymphatic vessel invasion. That is consistent with 
a report by Erčulj et al. (Erculj et al. 2012).  
 
Expression and Activity of the 26S-Proteasome 
Upregulation of the proteasomal subunits PSMA6, PSMB4, PSMC2 and PSMD12 
was demonstrated in hepatocellular carcinomas of p21-HBx transgenic mice by using 
MALDI-TOF analysis (Cui et al. 2006). By applying small interfering (si) RNA 
screening in human glioblastoma cells, Thaker et al. were able to identify 55 survival 
genes encoding proteases, kinases and transferases, of which twelve were subunits 
of the 26S-proteasome, including PSMB4 (Thaker et al. 2009), suggesting a role for 
different gene expression of proteasomal subunits in the development of various 
malignant tumours. Our study demonstrates that gene expression of proteasomal 
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subunits is generally increased in pulmonary neuroendocrine tumours compared to 
non-tumorous lung tissue. In particular, PSMB4 is associated with the potential for 
proliferation in these neoplasias and differs significantly between the different 
subgroups of pulmonary NET. PSMB4 expression levels interfere with numerous 
cellular processes involved in malignant transformations, such as cell cycle 
regulation, proliferation and apoptosis, promoting further malignant transformation 
along with EMT. Present studies identified increased proteasome and especially 
PSMB4 expression in different malignant tumours, suggesting it may be a survival 
gene in cancer (Kumatori et al. 1990; Kanayama et al. 1991; Choi 2001; Cui et al. 
2006; Thaker et al. 2009). In particular, the ubiquitin-proteasome system has been 
shown to play a complex role in the regulation of apoptosis, in which inhibition of the 
system has both pro-apoptotic and anti-apoptotic effects (Naujokat and Hoffmann 
2002). The activation of NFκB by proteasomes through degradation of IκB induces 
the expression of anti-apoptotic members of the Bcl-2 family (Catz and Johnson 
2001). Additionally, proteasomes degrade pro-apoptotic proteins, including BAX and 
BID (Breitschopf et al. 2000; Li and Dou 2000). 
A study into the inhibition of neuroendocrine lung tumours with bortezomib 
(Velcade®), the first and currently only FDA-approved proteasome inhibition, has 
recently begun in our laboratory. 
 
Conclusion 
To summarize the data generated for this doctoral thesis and reviewing the literature, 
we hypothesise that there is adequate evidence that neuroendocrine tumours should 
be viewed as an overall biological family of neoplasms. Despite the currently 
undisputed traditional morphological view and classification into carcinoids, LCNECs 
and SCLCs, our results will hopefully spur a re-evaluation of the current distinction 
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between SCLCs and NSCLCs by complementing it with a more biologically driven 
classification. The family of pulmonary neuroendocrine tumours, although showing 
different morphological presentation, age of onset and clinical outcome, can be 
biologically well distinguished from all other forms of lung cancers. Grouping LCNECs 
with SCLCs may allow for a more tumour adapted oncological management of those 
conditions. Notably, carcinoids should be separated from pulmonary neuroendocrine 
carcinomas, forming a different subgroup of NE tumours. Nevertheless, both 
subtypes of pulmonary neuroendocrine tumours cluster together and can be clearly 
separated from other forms of lung neoplasia. A more profound biological 
understanding of both carcinoids and neuroendocrine lung carcinomas might 
increase the chance of finding novel therapeutic targets, thereby leading to a more 
personalized therapeutic concept for this group of malignancies. 
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5. Results at a Glance 
 
Figure 31 Overview of differences in signalling pathways and cellular processes between 
pulmonary neuroendocrine lung tumours. Red arrows indicate activation, green arrows 
downregulation of different key players for important cellular pathways. Also markers 
important for prognosis (OS/PFS) are highlighted. Of note are the different entries into the 
cell cycle between carcinoids and carcinomas and the strong activation of angiogenesis in 
pulmonary carcinoid tumours. 
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6. Synopsis 
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for more 
than 40,000 deaths each year in Germany. Twenty-five percent of all lung tumours belong to 
the group of neuroendocrine tumours, encompassing typical (TC) and atypical carcinoids 
(AC), large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC). 
Even though all four subgroups share some morphological and molecular properties, it is still 
unclear whether they are different biological entities or form one distinct tumour entity 
displaying different grades of differentiation. They were previously reported to arise from 
serotonin producing pulmonary neuroendocrine cells (PNEC). It is suggested that LCNEC 
and SCLC originate from the same or similar precursor cells. However, it remains unclear 
how carcinoids can be integrated into this scheme. 
In order to address this question, 74 representative tumour specimens were used for 
sequencing analysis performed on a MiSeq instrument covering the 221 most important 
mutation hotspots related to human neoplasias. Additionally, mRNA-expression profiles of 80 
tumour samples were determined for 91 selected genes using NanoString nCounter 
technology. Furthermore, three unequivocal samples of each tumour entity were chosen to 
be tested for their miRNA signature via 384 well TaqMan low-density array real-time qPCR 
for the expression of 768 unique miRNAs. Finally, the pulmonary neuroendocrine tumour 
samples were analysed via TaqMan qPCR and immunohistochemistry for expression of the 
five most important subunits of the 26S proteasome. 
44 miRNAs were identified which showed a significantly different miRNA expression between 
the subtypes of pulmonary neuroendocrine tumours. For 12 miRNAs, the difference was 
highly significant (p<0.01). Eight of these were negatively correlated with the grade of tumour 
biology, the other four were positively correlated. Six miRNAs are significantly associated 
with survival. The mRNA expression analysis showed 48 significant correlations with tumour 
type. Sixteen most significant (p≤0.001), 20 highly significant (p≤0.01) and 12 significant 
(p≤0.05) candidates were identified. Nine significant correlations with progression-free 
survival were found. Overall survival correlated significantly with nine genes. Of the 643 
variants that passed the applied filter processing as described above, 122 variants were 
related to TC, 150 to AC, 164 to LCNEC and the final 207 variants were detected in the 
SCLC samples. We found a number of molecular features associated with pulmonary 
neuroendocrine tumours.  
In summary, we hypothesise that there is adequate evidence that neuroendocrine tumours 
should be considered an overall biological family of neoplasms. The family of pulmonary 
neuroendocrine tumours can be biologically well distinguished from all other forms of lung 
cancers. Additionally, better biological understanding of carcinoids and neuroendocrine lung 
carcinomas will increase the chance of finding new drug targets, maybe resulting in a more 
personalized therapeutic concept for this group of malignancies. 
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8. List of Abbreviations Used  
Abbreviation  Full Name 
AAH Atypical adenomatous hyperplasia 
AC Atypical carcinoid 
ADC Adenocarcinomas 
ASCO American Society of Clinical Oncology 
BAC Bronchoalveolar carcinoma in situ 
BASC Bronchoalveolar stem cell 
BLAST Basic Local Alignment Search Tool 
CC Cell cycle 
CDS Coding sequence 
CGH Comparative genomic hybridisation  
CNV Copy number variation 
COLD-PCR Co-amplification at lower denaturation temperature PCR 
CR Complete remission 
Ct Cycle threshold 
DIPNECH Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
DISC Death inducing signalling complex 
DST Downstream targets 
EMA European Medicines Agency 
EMT Epithelial to mesenchymal transition 
ESMO European Society of Medical Oncology 
FDA Food and Drug Administration 
FFPE Formalin fixed paraffin embedded 
FRET Förster resonance energy transfer 
GABA Gamma-aminobutyric acid 
GF Growth factor 
GO Gene ontology 
HE Haematoxylin and eosin staining 
HG High grade 
HPF High power field 
HR Hazard ratio 
IASLC International Association for the Study on Lung Cancer 
IGV Integrative Genome Viewer 
IHC Immunohistochemistry 
IMDA Isothermal multiple displacement amplification 
LAR Long-acting repeatable 
LCNEC Large-cell neuroendocrine cancer 
LG Low grade 
LOF Loss of function 
LOH Loss of heterozygousity 
MIQE 
Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments 
miRNA Micro RNA 
mRNA Messenger RNA 
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Abbreviation  Full Name 
NE  Neuroendocrine 
NEB Neuroepithelial body 
NELC Neuroendocrine lung cancer 
NET Neuroendocrine tumour 
NGS Next-generation sequencing 
NSCLC Non-small cell lung cancer 
NTC Non-template control 
OS Overall Survival 
PCR Polymerase chain reaction 
PD Progressive disease 
PFS Progression Free Survival 
PNEC Pulmonary neuroendocrine cells 
PR Partial remission 
PSA Polysialic acid 
qPCR Quantitative PCR 
RISC RNA-induced silencing complex 
ROI Region of interest  
RTK Receptor tyrosine kinase 
RTK Receptor tyrosine kinase 
SCC Small-cell cancer 
SCLC Small-cell lung cancer 
SD Stable disease 
SNP Single nucleotide polymorphism 
SQCC Squamous cell carcinoma 
TC Typical carcinoid 
TSCP TruSeq Amplicon Cancer Panel 
TSG Tumour suppressor gene 
WGA Whole-genome amplification 
WGS Whole-genome sequencing 
WHO World Health Organisation 
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9. List of Figures 
Figure 1: Incidence and mortality rates of different cancers, evaluated by the WHO 
World Cancer Report 2008 for the European region (Boyle 2008). Lung cancer 
accounts for more deaths than the next four most lethal cancer types combined. 
Figure 2 Current model for the cells of origin of the main types of lung cancer. An 
Ash1 expressing precursor cell is considered a stem cell giving rise to pulmonary 
neuroendocrine cells (PNECs), but also bronchoalveolar stem cells (BASC) and 
basal cell progenitors. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIPNECH) and tumourlets comprise precursor lesions for pulmonary carcinoids, 
while for LCNEC and SCLC no precursor lesions have been identified. For 
adenocarcinoma, the precursor lesions seem to be atypical adenomatous 
hyperplasia (AAH) and bronchoalveolar carcinoma in situ (BAC). for squamous cell 
carcinoma, the bronchial squamous dysplasia is a suspected precursor lesion. 
(Swarts et al. 2012) C: central; P: lung periphery 
Figure 3 Tumorigenesis model for pulmonary neuroendocrine tumours excluding 
LCNEC.  Precursor lesions are indicated in the grey area. The occurrences of 
specific aberrations in the primary tumour are shown. The dotted lines indicate 
hypothetical relationships (Swarts et al. 2012). C: central; P: lung periphery 
Figure 4 Typical carcinoid stained with haematoxylin and eosin (HE) showing 
neuroendocrine features such as rosettes (marked) and granular chromatin (400x 
magnification). Note the dense vascularisation of the tumour tissue. 
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Figure 5 Atypical carcinoid with two rosette structures (circles) and “salt and pepper 
chromatin” (arrow) stained with HE (400x magnification). 
Figure 6 Large-cell lung cancer forming a so-called palisade structure (400x 
magnification).Figure 7 Small-cell lung cancer with HE staining (400x magnification). 
The neuroendocrine properties like granular chromatin and lack of prominent nucleoli 
serve as diagnostic criteria for diagnosis of SCLC. 
Figure 7 Small-cell lung cancer with HE staining (400x magnification). The 
neuroendocrine properties like granular chromatin and lack of prominent nucleoli 
serve as diagnostic criteria for diagnosis of SCLC. 
Figure 8 Suggested algorithm for the treatment of non-small cell pulmonary 
neuroendocrine tumours (Gridelli et al. 2013). 
Figure 9 Boxplots depicting significant differences in miRNA expression in 
neuroendocrine pulmonary tumours. Expression of miR-18a and miR-15b* is 
increasing with increasing malignancy of the tumour. miR-335* and miR-1201 profiles 
show a decreased expression in carcinoids compared to the neuroendocrine 
carcinomas. For miR-22 and miR-367* increased malignancy is associated with 
decreased expression. In SCLC, miR-504 expression is dramatically decreased and 
for miR-513C, TC show the highest expression. 
Figure 10 Boxplots showing the expression profiles of the miR-29 family displaying 
similar patterns between the different tumour entities. Decreasing expression of miR-
29a-c correlates with increasing malignancy of the tumour. 
Figure 11 Pie chart showing results of the pathway analysis in pulmonary 
neuroendocrine tumours: The pathways showing the most prominent alterations by 
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miRNAs were shown to be the MAPK pathway followed by PI3K- and TGF-β-
pathway. Aberrations could also be found for Wnt-signalling, NFB-pathway, JNK-
pathway and mTOR-signalling. 
Figure 12 Illustrated results of the GO analysis presenting most hits in gene 
expression and transcription. Similar hits for cell cycle and nervous system were 
found. Following, with decreasing impact, also proliferation, immune response, 
apoptosis, DNA-damage-response, growth factors and signalling, carriers, 
angiogenesis and expression of structural compounds is affected by differential 
miRNA expression. 
Figure 13 mRNA expression patterns of different genes measured by the NanoString 
technology. All illustrated genes decrease in their gene expression with increasing 
malignancy of the NET. FOLR1, CDK6 and SYP show very low median expression 
levels in NE carcinomas, especially when compared to pulmonary carcinoids. MLH1 
is significantly higher in carcinoids then in high-grade tumours, but also carcinomas 
still have a noteable expression level. CHGA was the strongest expressed gene of all 
targets. Its y-axis is logarithmically scaled. 
Figure 14 mRNA expression patterns of different genes measured by the NanoString 
technology are shown. All illustrated genes increase in their expression level with 
higher aggressiveness of the tumour. TYMS, CDKN2A and SOX4 show nearly no 
expression in carcinoid tumours but a detectable (LCNEC) to strong (SCLC) 
expression in high-grade carcinomas. PAX6, RBP1 and SOX11 are absent in 
carcinoids and LCNEC but expressed in SCLC. 
Figure 15 The boxplots present mRNA expression pattern of BCL2 investigated by 
NanoString nCounter technology and the BCL2/BAX-ratio as marker for evade of 
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apoptosis, respectively. The BCL2 expression increases with increasing malignancy 
of the tumour entity. Whereas the BCL2/BAX ratio is nearly even in TC, the potential 
to evade apoptosis increases from AC over LCNEC to the highest value in SCLC. 
Figure 16 Kaplan-Meier curves for significant results regarding expression-dependent 
PFS in the group of high-grade pulmonary NET. A high expression level of NTS and 
HIF1A is associated with shortened time to progression, respectively. Low level 
expression of FOLR1 leads to an early recurrence of the tumour, whereas in contrast 
a loss of OCT4 expression is associated with prolonged PFS in this group of 
tumours. 
Figure 17 Kaplan-Meier curves for significant results regarding expression-dependent 
OS. A low PAX6 or OCT4 expression is associated with prolonged, a low FPGS or 
MAN2B1 expression is associated with shortened overall survival in LCNEC and 
SCLC, respectively. 
Figure 18 The chart pies summarises the algorithm used for variant filtering. Starting 
from 25,940 variants detected with the preliminary variant calling, going on with 
removing of synonymous variants that led to 18,899 variants. After a final filtering of 
variants below 10% of total reads or less than 25 mutated reads absolute 634 
variants were determined. 
Figure 19 The histogram demonstrates the distribution of the reads past filter (PF) 
from all targets and runs. The y-axis shows the number of clusters that passed the 
initial filter process, the x-axis shows the coverage of these loci merged from each 
sample. Most targets had a median coverage between 500 and 2,000bp. 
Figure 20 Samples showing at least one TP53 variant regarding the tumour entity. 
The number of mutated samples increased from TC (below 30%) to SCLC (more 
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than 90%). A sharp edge can be seen between carcinoid tumours (30%-40%) and 
high-grade carcinomas (75-95%). 
Figure 21 Kaplan-Meier curves of significant results regarding FBXW7. The 
occurrence of mutations within the coding sequence of FBXW7 is associated with 
shortened cumulative overall survival. 
Figure 22 Kaplan-Meier curves of significant results regarding the mutation-
dependent PFS analysis. Patients showing mutations in the CDS of either MET or 
KRAS have a highly significant shortened time to progression of the tumours. Also 
ATM and RB1 mutations significantly impact to progression of the tumours. 
Figure 23 Box plots illustrating significantly upregulated mRNA expression in the 
different subtypes of pulmonary neuroendocrine tumours are shown. The gene 
expression measured by TaqMan qPCR is shown using log(2^-dCt) of each target. 
Horizontal bars indicate significant dependences. Note that any proteasomal subunit 
mRNA expression is significantly upregulated compared to controls obtained from 
non-tumorous lung tissue of patients with pneumothorax. Especially PSMB4 and 
PSMD1 show the strongest upregulation compared to benign lung. LCNEC show the 
broadest range of proteasomal expression pattern, maybe due to the heterogeneity 
of this entity. Remarkable is the relatively low PSMA5 expression level when 
compared to the control. 
Figure 24 The figure illustrates the results of the immunohistochemical staining of the 
proteasomal subunit PSMB4 in both, low-grade (A+B) and high-grade (C+D) 
pulmonary NET. Immunohistochemically, PSMB4 reactivity is strong in any subtypes 
of pulmonary NET. All NET are silhouetted against the encircling stroma. 
 
 
128 
Immunohistochemical no differences between the four tumour entities could be 
detected. 
Figure 25  Boxplot of PSMB4 expression levels between the different tumour types. 
In particular, the PSMB4 mRNA expression is upregulated in pulmonary NET 
compared to controls and differs significantly among the subtypes of pulmonary NET. 
PSMB4 shows the highest expression in LCNEC, the lowest expression in AC and 
SCLC. Nevertheless, immunohistochemically no differences between the four tumour 
entities could be detected, PSMB4 mRNA expression is higher in LCNEC/SCLC than 
in TC/AC. The gene expression measured by TaqMan qPCR is shown using log(2^-
dCt) of each target. Horizontal bars indicate significant dependences. 
Figure 26 Differential expression of PSMB4 between the two types of high-grade 
NELC. LCNEC shows a slightly higher expression level then SCLC. The gene 
expression measured by TaqMan qPCR is shown using log(2^-dCt) of each target. 
Horizontal bars indicate significant dependences. 
Figure 27 Differential expression pattern of PSMA1 and PSMB5 in low-grade NELC. 
Among others, the gene expressions of PSMA1 (p= 0.030) and PSMB5 (p= 0.035) 
are significantly higher in TC compared to AC. The gene expression measured by 
TaqMan qPCR is shown using log(2^-dCt) of each target. Horizontal bars indicate 
significant dependences. 
Figure 28 Boxplots illustrating results of the immunohistochemical staining of NELC 
against the neuroendocrine markers NCAM (CD56) and CHGA, CKMNF-116 and 
TTF1 as diagnostic standards, Ki67 for proliferation and CASP3 to determine the 
apoptotic activity fraction. 
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Figure 29 The visual analysis of the next generation sequencing data by integrative 
genomics viewer shows a high background of false-positive variants for APC exon 
14. Pink bars show sequenced forward strand, blue bars show sequenced reverse 
strands. Colour dots within the strands display discrepancies between the base calls 
and the hg19 reference build. 
Figure 30 Proposal for a model for classifying lung tumours. Despite the traditional 
morphologic view and classification into NSCLC and SCLC, which has been 
undisputed for generations of medical doctors, the family of pulmonary 
neuroendocrine tumours, although showing different morphological presentation, can 
be biologically distinguished from all other forms of lung cancers. 
Figure 31 Overview of differences in signalling pathways and cellular processes 
between pulmonary neuroendocrine lung tumours. Red arrows indicate activation, 
green arrows downregulation of different key players for important cellular pathways. 
Also markers important for prognosis (OS/PFS) are highlighted. Of note are the 
different entries into the cell cycle between carcinoids and carcinomas and the strong 
activation of angiogenesis in pulmonary carcinoid tumours. 
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10. List of Tables 
Table 1. Comparison of clinical parameters from patients suffering from NET 
(Asamura et al. 2006). 
Table 2 Summary of meta-analyses of the results of studies on candidate 
immunohistochemistry markers for survival of patients with non-small cell lung cancer 
(Zhu et al. 2006). 
Table 3 Molecular characteristics that distinguish lung carcinoids from SCLC (Swarts 
et al. 2012). 
Table 4 Comparison of the different high-throughput methods used. 
Table 5 Summary of investigated genes provided by the TruSeq Amplicon-Cancer 
Panel. 
Table 6 Summary of investigated genes involved in different pathways or cellular 
mechanisms. 
Table 7 Pretreatment protocols and dilutions of the different used antibodies. 
Table 8 Detected significant association of miRNA expression with tumour type. 
Highly significant miRNAs are bolded. Data are presented in Figure 9 and 18. 
Table 9 Calculated p-values of miRNA expression regarding OS using COXPH. 
Highly significant miRNAs are bolded; most significant miRNAs are highlighted grey. 
Table 10 Significant p-values of mRNA expression correlating with tumour type 
calculated by the Kruskal Wallis Rank Sum Test are shown. Highly significant 
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mRNAs are bolded; most significant mRNAs are highlighted grey. Highlighted genes 
are presented in boxplots in Figure 13. 
Table 11 Significant p-values of mRNA expression correlating with tumour grade 
calculated with the Spearman Test. Highly significant mRNAs are bolded; most 
significant mRNAs are highlighted grey. 
Table 12 P-values of mRNA expression regarding several clinical variables (TNM) 
using the Spearman Test are shown. Highly significant mRNAs are bolded; most 
significant mRNAs are highlighted in grey. 
Table 13 Overview of the technical run parameters for all five MiSeq runs. In run 5, 
the 23 samples with the lowest median coverage or insufficient representation of 
some loci were resequenced. 
Table 14 The table shows the results of the variant calling. The mutation frequency 
per gene as well as the percentage of samples of each entity showing at least one 
mutation at this locus is illustrated. 
Table 15 Summary of significant results regarding the mutation-dependent survival 
analysis. 
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